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Tremendous progress in treatment and outcomes has been achieved across the whole range of haematological 
malignancies in the past two decades. Although cure rates for aggressive malignancies have increased, nowhere has 
progress been more impactful than in the management of typically incurable forms of haematological cancer. Population-
based data have shown that 5-year survival for patients with chronic myelogenous and chronic lymphocytic leukaemia, 
indolent B-cell lymphomas, and multiple myeloma has improved markedly. This improvement is a result of substantial 
changes in disease management strategies in these malignancies. Several haematological malignancies are now chronic 
diseases that are treated with continuously administered therapies that have unique side-effects over time. In this 
Commission, an international panel of clinicians, clinical investigators, methodologists, regulators, and patient advocates 
representing a broad range of academic and clinical cancer expertise examine adverse events in haematological 
malignancies. The issues pertaining to assessment of adverse events examined here are relevant to a range of 
malignancies and have been, to date, underexplored in the context of haematology. The aim of this Commission is to 
improve toxicity assessment in clinical trials in haematological malignancies by critically examining the current process 
of adverse event assessment, highlighting the need to incorporate patient-reported outcomes, addressing issues unique 
to stem-cell transplantation and survivorship, appraising challenges in regulatory approval, and evaluating toxicity in 
real-world patients. We have identified a range of priority issues in these areas and defined potential solutions to 
challenges associated with adverse event assessment in the current treatment landscape of haematological malignancies.
Introduction: Haematological malignancies and 
their therapies have changed
The haematological malignancies have been the model for 
chemotherapy, radiotherapy, molecularly targeted oral 
drugs, and an array of immunotherapies (table 1). These 
treatment modalities are incorporated into different 
disease types and result in a variety of adverse events—
some well characterised, others less well understood. New 
treatments have changed the natural history of many of 
these diseases. Chronic or continuous therapy given for 
years or indefinitely is now the standard for some 
haematological malignancies. Even for haematological 
malignancies treated with shorter-term, conventional 
cytotoxic drugs with curative intent, there is increasing 
recognition of late-term and long-term adverse events that 
affect patients for years and decades after treatment. Our 
understanding of the patient’s experience of treatment 
toxicity has changed substantially.
Lymphoma treatment is an exemplar of changing 
therapies in haematological malignancies, and the 
increasing use of new, continuously administered drugs. 
The proliferation of molecularly targeted drugs and 
immunotherapy to treat lymphoma shows the treat ment 
shift seen across many haematological malignancies 
(figure 1). Indolent forms of lympho proliferative disorders, 
such as chronic lymphocytic leukaemia and follicular 
lymphoma, have long been treated as chronic diseases, 
but the availability of novel therapeutics has shifted 
disease management strategies. Whereas historically, 
treatment was largely episodic and finite (ie, a set number 
of cycles of chemotherapy), many patients now receive 
continuous oral therapy for relapsed disease1 or even 
first-line therapy.2 Patients taking ibrutinib, approved by 
the US Food and Drug Administration (FDA) as first-line 
therapy for chronic lymphocytic leukaemia, have a median 
progression-free survival in excess of 3 years, and both 
idelalisib3 and venetoclax4 (each approved for relapsed 
chronic lymphocytic leukaemia) share the model of 
continuous oral therapy, in which treatments are ad-
ministered until progression or intolerance. Follicular 
lymphoma is also shifting towards a chronic therapy 
model, with maintenance intravenous mono clonal 
antibodies (rituximab or obinutuzumab5,6), or with 
continuous oral drugs. Idelalisib is FDA-approved in 
the USA for relapsed follicular lymphoma,7 ibrutinib is 
approved for Waldenström macroglobulinemia,8 and a 
host of other oral, continuously administered drugs are in 
active development internationally.
Among lymphomas treated with conventional cytotoxic 
drugs in the short-term for curative intent, a deeper 
recognition of late-term adverse events has led to an 
evolution in treatment. In Hodgkin’s lymphoma, limited-
stage disease was previously managed with high-dose 
radiation therapy, and advanced disease was treated with 
a combination of chemotherapy and radiotherapy.9,10 The 
late toxicity of these treatment approaches (eg, second-
ary malignancies, heart disease, and pulmonary 
complica tions) resulted in more treatment-related deaths 
from complications of survival than deaths from disease. 
Hodgkin’s lymphoma is now managed with de-escalation 
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approaches, with fewer cycles of chemotherapy and less 
radiotherapy than previously, where possible.11,12 In 
non-Hodgkin lymphoma, the addition of rituximab to 
chemotherapy improved overall survival in patients with 
diffuse large B-cell lymphoma13–15 but introduced un-
expected late-term toxicities, such polyoma virus 
reactivation.16
Outcomes for patients with multiple myeloma have 
improved substantially in the past decade because of the 
increased use of high-dose therapy and the addition of 
thalidomide, bortezomib, and lenalidomide along with 
improved supportive care measures.10,17 Several new 
drugs have become available in the past 5 years, including 
pomalidomide, carfilzomib, panobinostat, ixazomib, 
elotuzumab, and daratumumab. The standard of care is 
triplet therapy with the advent of these new therapies.18–20 
Venetoclax is now a promising targeted therapy for 
relapsed or refractory t(11;14) multiple myeloma.21 Facing 
a multitude of immuno modulators, targeted drugs, and 
immunotherapies, the nature of treatment toxicity that 
patients with multiple myeloma have has changed 
substantially in the past decade.
Perhaps no haematological malignancy exemplifies 
the shift in treatment and the resultant difference in 
toxicity profiles better than chronic myelogenous 
leukaemia, which is now treated almost exclusively with 
oral BCR–ABL tyrosine kinase inhibitors. Drugs of this 
class, initially imatinib, have now been expanded to 
include dasatinib, nilotinib, bosutinib, radotinib, and 
ponatinib. These continuously administer ed drugs have 
resulted in life expectancy that approximates that of the 
age-matched normal population.22 Along with improved 
survival, these drugs introduced a host of novel toxicities 
and elucidated the importance of adherence with oral 
therapies. Adherence with imatinib treatment of 90% or 
less is associated with a 28·5% probability of a major 
molecular response, whereas the probability is 94% 
when adherence is more than 90% (p<0·001).23 Less 
than 80% adherence to imatinib treatment yielded a very 
low likelihood of molecular response.23 Yet only 32·7% of 
patients with chronic myelogenous leukaemia are highly 
adherent to therapy. Specific side-effects related to 
treatment of chronic myelogenous leukaemia had a 
substantial prognostic effect on the level of intentional 
non-adherence, and those patients whose side-effects 
were well managed were more likely to belong to the 
highly adherent group.24,25
Treatment of myeloid malignancies other than chronic 
myelogenous leukaemia has also evolved and now 
includes several continuously administered drugs. 
Lenalidomide has improved the outcomes of patients 
with myelo dysplastic syndromes and the cytogenetic 
abnormality del(5q) by giving transfusion independence 
and improving quality of life.26 Patients with higher-risk 
myelodysplastic syndromes, who historically lacked 
effective treatment options, can now take maintenance 
hypomethylating drugs, allowing some patients to live 
with the disease as a chronic illness.27 In the acute 
myeloid leukaemias, oral targeted therapies such as the 
FLT3 inhibitor midostaurin are being used in addition to 
conventional cytotoxic induction regimens.28 Enasidenib, 
an IDH2 inhibitor, is a continuously ad ministered oral 
monotherapy for relapsed or refractory disease.29
The landscape of haematological malignancies has 
been changed not only by continuously administered 
targeted therapies but also by advances in immunotherapy 




Anti-CD20 antibodies Rituximab, rituximab and 
hyaluronidase, ofatumumab, 
obinutuzumab
Radiolabelled antibodies Ibritumomab tiuxetan
Antibody–drug conjugate




Anti-CD22 antibody conjugated to 
a calicheamicin-derived cytotoxic 
moiety
Inotuzumab ozogamicin




PD-1 antibody Nivolumab, pembrolizumab
Other antibodies Lirilumab, atezolizumab, 
avelumab, durvalumab
Immunomodulating drugs Lenalidomide, pomalidomide
Chimeric antigen receptor T-cell therapy Tisagenlecleucel (CTL019), 
axicabtagene ciloleucel
Cellular therapy




Cytokines Granulocyte colony-stimulating 
factor, granulocyte macrophage 
colony-stimulating factor
Interleukins Interleukin-2
Cancer vaccines Ongoing development
Molecularly targeted therapy
B-cell receptor inhibitors
Bruton’s tyrosine kinase inhibitor Ibrutinib, acalabrutinib
Phosphoinositide 3-kinase inhibitor Idelalisib, copanlisib
Tyrosine kinase inhibitors Imatinib, nilotinib, dasatinib, 
bosutinib, ponatinib
Hypomethylating drugs 5-azacytdine, decitabine
BCL2 inhibitor Venetoclax
Isocitrate dehydrogenase 2 inhibitors Enasidenib
FLT3 inhibitors Midostaurin, sorafenib
mTOR inhibitors
mTOR type 1 inhibitor Everolimus
Table 1: Examples of immunotherapy and molecularly targeted therapy 
now used in the treatment of haematological malignancies
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blinatumomab for acute lymphocytic leukaemia,30 
immune checkpoint inhibitors such as pembrolizumab 
and nivolumab for Hodgkin’s lymphoma,31,32 and the 
advent of chimeric antigen receptors (CAR) T cells33 for 
relapsed non-Hodgkin lymphoma, have also brought 
new risk and new categories of adverse events.
The result of treatment changes across haematological 
malignancies is that increasing numbers of patients are 
living with the challenge of managing not just their 
disease, but also, in some cases, continuous therapies 
with new, chronic toxic effects. In this Commission, an 
international expert panel of doctors, clinical investi-
gators, researchers, methodologists, reg ulators, and 
patient advocates collaborated to identify and begin to 
address the challenges of assessing adverse events in 
clinical trials in this modern era of haematological 
malignancies. Although several sections of this 
initiative are relevant to malignancies in general and 
not just haematological cancers, the aim of this 
Commission is to highlight the relevance of developing 
a more comprehen sive, accurate, and patient-focused 
assessment of toxic effects in haematology clinical 
trials, both in industry-sponsored trials and in 
investigator-initiated studies. We begin by proposing 
improvements in the process of adverse event 
assessment in trials and by emphasising the inclusion 
of patient-reported outcomes (PROs) in haematology 
trials. Unique issues pertaining to haemo poietic stem-
cell transplantation (HSCT) and late toxic effects in 
survivors of haematological malignancy will then be 
explored. Challenges of the assessment in the context 
of the regulatory approval of new drugs will then be 
assessed, followed by a discussion on implementation 
of improved toxicity assessment in real-world, non-
study patients treated in routine clinical practice in all 
parts of the world. In each section, challenges inherent 
to toxicity assessment will be described and proposed 
solutions put forth. In the concluding section, we will 
define actionable targets for improvements in the 
assessment of adverse events in haematology, with a 
goal of defining the path forward.
Section 1: Current processes in adverse event 
assessment: strengths and shortcomings
Numerous challenges and potential solutions to 
improving assessment of adverse events exist in 
haematology, and inherent to these are an understanding 
of the strengths and shortcomings of the approach to 
toxicity assessment at present. New and often 
continuously administered therapies for haematological 
malignancies bring with them a different range of 
toxicities, including an increasing number of long-term, 
symptomatic side-effects that challenge the traditional 
approaches to collecting and communicating drug-
related adverse events. In this section we address the 
existing processes for defining and analysing adverse 
events and begin to introduce innovations in how to 
better capture and analyse toxicity data in clinical trials. 
We also discuss how optimising adverse event 
assessment could affect the drug development process. 
Most of this section is deliberately tumour-agnostic, and 
the challenges and solutions identified here are 
applicable to a range of cancer clinical trials, but we 
conclude this section with issues pertaining to adverse 
event assessment that are unique to haematology.
Processes for standardisation of terminology for 
adverse events
The initial steps in the development of new drugs require 
harmonised systems for patient-safety monitoring that 
can be used internationally. The National Cancer 
Institute’s (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE) is one such system.34 Although 
the most recent CTCAE (version 5.0) has international 
acceptance for establishing severity-based adverse event 
grading, other international systems use Medical 
Dictionary for Regulatory Activities (MedDRA) termin-
ology to describe adverse events. The purpose of the 
CTCAE is to provide standards for the description and 
exchange of safety information of new cancer therapies 
and treatment modalities in haematology and oncology. 
It is used to define protocol parameters, such as 
maximum tolerated dose and dose-limiting toxicity, and 
Figure 1: Evolution of therapy in haematological malignancies: lymphoma as an example of shifting treatment strategies
MOPP=mustine, vincristine, procarbazine, and prednisone. CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone. R-CHOP=rituximab 
plus CHOP. ABVD=adriamycin, bleomycin, vinblastine, dacarbazine. BEACOPP=bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, 
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to provide eligibility parameters and guidance for dose 
modification. The original version of the CTCAE from 
1982 included 49 adverse event terms grouped in 
18 categories, each with criteria for grading the severity 
of the adverse event. CTCAE version 3.0 was the first 
uniform and comprehensive dictionary of adverse event 
grading criteria for use by all modalities for the treatment 
of cancer and included criteria relevant to surgical, 
radiation, and paediatric-based clinical trials. The 
adoption of MedDRA terminology by the International 
Conference on Harmonization (ICH), the NCI, industry, 
and regulatory bodies provided the impetus for the NCI 
to redesign the CTCAE in 2008 to be harmonised with 
MedDRA. The most recent version of the CTCAE, 
from 2017, has 837 terms, updated grading information, 
and a comprehensive index.
Improving analysis of adverse events: aggregated 
safety analysis, graphic readouts, and depicting the 
time profile of adverse events
Precise, consensus definitions of adverse events and 
their severity are as important as a consensus method of 
analysing and presenting adverse event data. Existing 
methods of analysis fall short in describing toxicities of 
modern therapies for haematological malignancies. 
Typically, adverse event data are presented in a clinical 
trial report as a summary table of the high-grade toxicity 
in any patient during the course of the trial. These tables 
provide an efficient display of the safety assessment of a 
drug based on the number and percentage of high-grade 
events. However, they provide no information on the 
trajectory of the adverse events, their onset, progression, 
or cumulative effects, which might substantially affect 
tolerability.35 In addition to standardising the terminology 
and grading the effects, it is useful to define adverse 
effects in relation to timing of drug exposure (panel 1).
Longitudinal graphs of the prevalence of specific adverse 
events would provide more information about how they 
arise and whether the effect becomes cumulative or 
resolves with supportive care, dose modification, or 
therapy cycle or course. The NCI Web Reporting System, a 
tool being used in NCI-sponsored early phase clinical 
trials, facilitates graphical outputs of adverse event 
information and presents more comprehensive visual 
output of adverse event data than a conventional 
maximum grade table (figure 2). A pie chart can be used 
to illustrate the concept that the specific toxicity frequency 
is heterogeneous and that common toxicities can be 
overshadowed by the constellation of other toxicities that 
among themselves do not show up except when added 
together. The advantages of following toxicity over time 
and the limitations in collecting data on chronic toxicity in 
early-phase trials are illustrated in panels B–D of figure 2. 
The patients who remain in a study tend to be those who 
do not have toxicity, and patient attrition from the trial 
decreasing the number at risk gives the impression that 
treatment is more tolerable. Graphical displays that 
include the number at risk are more accurate.
The Toxicity over Time (ToxT) package36 is another tool 
for producing analytical and graphical outputs that include 
the time profile of adverse events and an assessment of 
the burden of chronic, low-grade adverse events. ToxT can 
be used for longitudinal analyses to depict the timeframe 
of adverse events in a variety of ways, including bar charts 
that show incidence and grade of adverse events by cycle, 
stream plots that show grade of adverse event by cycle, 
time-to-event analyses (figure 3), and an area-under-the-
curve analysis (AUC; figure 4). An AUC approach is 
particularly relevant to capturing the effect of chronic low-
grade toxicity. A patient with a continuous low-grade 
toxicity, such as continuous grade 2 diarrhoea (four to 
six stools above baseline daily) should be accounted for 
because their experience is potentially more substantial 
than a short-lived, isolated grade 3 toxicity. AUC provides 
this information in graphical and numerical form 
(figure 2B; figure 4). Existing methods do not sufficiently 
capture cumulative dose of drugs by using adverse event 
data from multiple cycles. These approaches have not yet 
been integrated prospectively into phase 1 designs but 
could help identify more tolerable dosing approaches. 
Other potential approaches to impro ving toxicity analysis 
might include preprogrammed algorithms that identify 
patterns of combined toxicities that portend added risk for 
severe events or development of syndromes (eg, cerebro-
vascular events, haemolytic uremic syn drome, cardio-
vascular events).
Challenges in dose and schedule determination in early-
phase haematology trials
Stepwise approaches streamline drug development and 
lead to the most efficient evaluation of new treatments. 
Throughout this development process, dose determination 
is driven by the accumulation of adverse events that are 
Panel 1: Definitions of toxicity relative to drug exposure, 
by drug category
Acute effects
Develop within a short and defined timeframe; can be transient 
or reversible or persistent.
Chronic effects
Develop over time to be a persistent and unremitting, or 
intermittent and recurring, series of events, extending past a 
defined interval such as the first cycle of therapy.
Cumulative effects
Develop and increase with repeated exposures to drug 
(progressive over time).
Late effects
Result in subclinical or asymptomatic physiological changes 
that do not result in immediate, intermittent, or short-term 
adverse clinical events, but rather are manifest over an 
extended timeframe.
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used in aggregate to identify the recommended dose and 
schedule for later-phase investigations. Given that many 
therapeutics for haematological malignancies are now 
administered over prolonged periods, clinical trial designs 
need to address dose determination and refinement 
beyond the phase 1 dose escalation. Definitions of dose-
limiting toxicity are generally based on single-cycle, acute 
adverse events that are of such sufficient severity that 
dosing cannot be continued at the given dose level. When 
developing non-cytotoxic, continuously, or chronically 
Figure 2: Graphical representations and analysis of adverse events by the National Cancer Institute Web Reporting Tool
(A) Pie chart of all treatment-emergent adverse events in patients treated with a vascular endothelial growth factor receptor inhibitor (VEGFR2i) and a DNA repair inhibitor (DNARi). (B) Risk-based 
monitoring of diarrhoea and hypertension in patients in a clinical trial of a VEGFR2i and a DNARi to assess the frequency of adverse events by course using an area-under-the-curve-based approach. 
(C) Hypertension in patients from five clinical trials of VEGFR2i assessed by grade, course number, and number of adverse events using a contour map. Below is graph that depicts the number of 
patients at risk by course. (D) Hypertension as a treatment-emergent adverse event in patients given VEGFR2i in a clinical trial assessed by grade, course number, and number of adverse events using a 
contour map. Below is a graph that depicts the number of patients at risk by course. PPE=Palmar-Plantar erythrodysesthesia.
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administered therapies, the relationship between dose-
response and toxicity might not be well understood, and 
assessing tolerability in such a short window might not be 
possible.37 Molecularly targeted and immunotherapy drugs 
might not have doses and schedules determined during 
the first cycle of therapy, leading to inexact descriptions of 
dose-limiting toxicity. This hampers establishing the 
maximum tolerated dose and the recommended 
phase 2 dose once dose escalation is completed.38
One way to address this issue is to lengthen the 
observation window for the dose-limiting toxicity to 
two or three cycles before establishing the recommended 
phase 2 dose and schedule. Alternatively, expansion 
cohorts could further characterise safety and tolerability 
of a treatment, which could lead to further dose and 
schedule refinement. Phase 2 trials evaluating safety, 
tolerability, activity, or efficacy of molecularly targeted or 
immunotherapy drugs could inform dose and schedule 
refinement. Improving the design of these trials to 
efficiently determine the dose and schedule is crucial.
At present, the short observation window for 
determining dose-limiting toxicity in phase 1 clinical trials 
does not permit the evaluation of lower grade, chronic 
toxicities that often lead to dose modification or delay in 
later cycles and affect tolerability. This compromises 
effective dose delivery and, in some instances, efficacy and 
alters the benefit–risk assessment of therapy over time. 
The effect of these low-grade toxicities on quality of life in 
patients with advanced disease could become intolerable 
with continuous administration, and the toxicities are 
often missed in the standard phase 1 trial evaluation 
window of dose-limiting toxicity.39,40 Inclusion of late or 
delayed adverse events to determine the recommended 
phase 2 dose is not standardised. Further study of dose-
limiting toxicities that occur outside the narrowly specified 
timeframe for adverse event assessment is required.
One adaptive design that could assist in the evaluation 
of chronic low-grade adverse events is the modified 
toxicity probability interval design,41 which uses all 
adverse event data gathered before dose escalation or 
de-escalation. The advantage is that each adverse event is 
used for dose selection irrespective of grade rather than 
only the adverse events in one cycle of therapy using 
three to six patients. The larger sample size increases the 
confidence that the recommended phase 2 dose will be 
safe and tolerable and that the schedule of a new drug 
will be clinically relevant, particularly when adverse 
events occur outside of the window of detection of the 
dose-limiting toxicity. However, a qualitative judgment 
analysis of the effect of chronic low-grade adverse events 
could be needed to evaluate the effect of therapy.
Challenges to the drug development process posed by 
chronic, cumulative, and late effects
The occurrence of chronic, cumulative, and late effects 
are inherent to many modern therapies for haematological 
malignancies, so longer-term follow-up of patients in 
both early-phase and later-phase trials might be needed to 
capture the relevant adverse event profile. One example of 
the need for novel trial designs and longer observation 
windows for dose-limiting toxicity comes from the 
analysis of 54 phase 1 trials of molecularly targeted 
drugs.38 Almost a quarter of the patients treated (n=599) 
who developed grade 3 or worse adverse events had their 
dose-limiting toxicity observed after their first cycle of 
treatment. Of the 2084 patients reviewed in this analysis, 
grade 2 adverse events such as diarrhoea, fatigue, and 
neutropenia were observed at the highest frequency in 
treatment cycles three to six, and not during cycle 1. 
Another example comes from a pooled analysis of 
576 patients receiving nivolumab for advanced 
melanoma.42 Adverse events of any grade occurred any 
time between 5 weeks (for skin toxicities) and 15 weeks 
(for renal toxicities) for median time to onset.
Figure 3: Time-to-event analyses for adverse events using the Toxicity over Time package
(A) Time to grade 2 or worse diarrhoea in patients given FOLFOX and IROX in NCCTG N9741.36 (B) Median time to 
first occurrence and worst grade toxic effects in patients given IROX in NCCTG N9741.36 The figures capture the 
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A greater challenge is capturing the contribution of 
toxicity attributable to a novel drug that occurs late in 
the overall therapeutic course. In classical Hodgkin’s 
lymphoma, where PD-1 blockade results in more than 
80% of patients achieving a partial or complete response 
in the relapsed and refractory setting,31 some severe life-
threatening complications were not seen until patients 
underwent allogeneic HSCT.43 This type of data relies on 
astute clinicians identifying the occurrence of toxicity in 
an unusual context or presentation. Other such 
examples include the identification of the association of 
progressive multifocal leukoencephalopathy16 with 
rituximab therapy in HIV-negative patients, hepatitis B 
reactivation with rituximab,44 delayed neutropenia with 
rituximab,45 and an association of ibrutinib with 
aspergillosis46 and arrhyth mias47 in patients with 
haematological malignancies. Because of the potential 
need for continuous therapy (in chronic myelogenous 
leukaemia, for example), longer follow-up might 
become particularly important as adverse events occur 
long after the mandatory monitoring period has ended. 
Furthermore, the pattern of adverse events when re-
starting therapy after a deliberate period off therapy 
might be different to those that appeared during initial 
therapy. For example, late toxicity of imatinib (eg, cardiac 
toxicity, abnormal bone and mineral metabolism, 
hypothyroidism) would not necessarily be observed in 
studies with exclusively short-term endpoints.48 A 
greater expectation of unexpected adverse events, which 
might occur either acutely or quite delayed, requires 
mandatory, longer-term surveillance if safety data are to 
be captured comprehensively. No formal mechanism 
exists for this type of surveillance activity, but it is 
crucial. Post-marketing surveillance for adverse events 
is further explored in sections 5 and 6.
The process of learning from one trial to inform the 
investigators and clinical practice in another trial needs 
to become increasingly rapid and dynamic, from both 
regulatory and sound clinical practice perspectives. The 
rapid roll-out of immunotherapies across tumour types 
and, concurrently, into regimens of multiple combin-
ations (including other novel therapies), each with a 
different profile of adverse events, has created regulatory 
challenges. Perhaps the most compelling examples are 
the seamless phase 1, phase 2, and phase 3 designs with 
large expansion cohorts used in some immunotherapy 
trials. The advantages of this type of design include the 
ability to rapidly identify areas of disease activity and 
move quickly to licensing strategies. International review 
boards have been challenged to assure patient safety 
because the quick dissemination of rapidly accrued safety 
information without the added safeguard of a data safety 
monitoring committee proved difficult. These problems 
were not insurmountable, but they did raise ethical 
concerns. The risk of not identifying the optimal recom-
mended phase 2 dose always exists when compiling non-
aggregated data.
The desire for quick-answer, short-conduct trials might 
also imepede the ability of investigators to define important 
longer-term toxicity. This could be addressed by introducing 
mandatory assessment of longer-term toxicity with long-
term follow-up of patients participating in late-phase 
clinical trials. Late-occurring toxic effects can adversely 
affect survival, and such effects can only be detected with 
adequate follow-up. For example, in early-stage classical 
Hodgkin’s lymphoma, the addition of radiotherapy 
to combination chemotherapy with ABVD (adriamycin, 
bleomycin, vinblastine, and dacarbazine) improves 
progression-free survival compared with ABVD alone, but 
overall survival might ultimately be compromised, probably 
because of the late effects of radiotherapy.49 Shorter-term 
Figure 4: AUC analysis to compare adverse events over time—conceptually and applied
(A) Conceptual example of AUC analysis with patient A, who has a continuous grade 2 adverse event and a higher 
AUC than patient B, who has an isolated grade 3 event. (B) Application of AUC analysis depicting mean diarrhoea 
grade over time in patients given FOLFOX and IROX for metastatic colorectal cancer in clinical trial Alliance/NCCTG 
N9741 (the p value compares the AUC numbers).34 AUC=area under the curve. IROX=irinotecan and oxaliplatin. 
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endpoints might have regulatory import ance in safety 
assessment, but assessment of longer-term benefit should 
not be de-emphasised.
Data informing late-term toxicity could also come 
from other sources such as post-hoc analyses, with 
social media and patient advocacy playing an important 
Panel 2: Immune-related adverse  events: a new context of adverse event assessment in haematological malignancies
Advances in immunotherapy, including immune checkpoint 
blocking antibodies, bispecific antibodies, and chimeric antigen 
receptor (CAR) T cells, have led to substantial practice-changing 
approaches in some haematological malignancies. They also 
introduce great complexity to the assessment of adverse events. 
The recent FDA approval of CAR T-cell therapy in the USA and the 
proliferation of these therapies in clinical trials for patients with 
relapsed haematological malignancies in many developed 
countries bring along a myriad of immune-related adverse events 
that are not well captured by existing assessment systems. These 
immunotherapy-related adverse events have brought new 
challenges to reporting, dose modifications, and subsequent 
patient management.
With respect to checkpoint blocking antibodies, the array of 
immune-related adverse events continues to grow, and with the 
need for continuous therapy in many cases, these adverse events 
arise at unpredictable times and their duration in some cases can 
be prolonged. Because of the efficacy of these drugs, the reporting 
of adverse events has been suboptimal, because of both 
investigators’ and patients’ bias toward not wanting to stop an 
effective therapy. Frequently occurring toxicities with checkpoint 
inhibitors include pruritus, maculopapular rash, thyroiditis, 
pneumonitis, diarrhoea, colitis, hepatitis, arthritis, myositis, 
nephritis, pericarditis, haematological toxicities, and neurologic 
toxicities. At what grade level these and other drugs must be 
discontinued, and in which circumstances to retreat, are not 
necessarily clear. Most clinically relevant immune-related adverse 
events occur early in therapy and are reversible with either the 
discontinuation of the drug or the administration of steroids 
(or other immune suppression), and these are for the most part 
reported. However, some of these adverse events occur late in 
therapy, some are recurrent with or without drug rechallenge, 
some are low-grade but chronic, and some have been fatal. It is 
these late-occurring, recurrent, or chronic, low-grade, 
immune-related adverse events that are underreported and 
clinically underappreciated. 
Additionally, the definition and recognition of an immune-
related adverse event is often the result of a best clinical 
judgement, which involves subjective consideration of a 
differential diagnosis and is rarely biopsy-proven (eg, ground 
glass opacities could be due to either infection or pneumonitis). 
As the range of these immune-related adverse events has become 
more defined and experience with their management has been 
gained, the recognition and grading of immune-related adverse 
events has become more standardised, and management has 
become increasingly prescribed with many sponsors using 
predefined case definitions. This alone will certainly improve the 
evaluation and reporting of immune-related adverse events with 
these new drugs. Formally standardising immune-related adverse 
events and case definitions in terms of type and grading across all 
studies will help further in this respect.53 Furthermore, 
incorporating both patient-reported and doctor-reported adverse 
events into clinical trials and after commercialisation will deepen 
the appreciation for how these immune-related adverse events 
affect a patient on continuous or long-term therapy.
CAR T-cell therapy, on the other hand, could pose the opposite 
problem. This therapy is acute, not continuous, and has a 
defined and relatively limited array of toxic effects largely falling 
into two distinct categories: cytokine release syndrome54 and 
neurotoxicity. The pathophysiology of cytokine release 
syndrome is fairly well understood, and the availability of 
effective therapies renders the risk largely time-limited and 
reversible. However, the pathophysiology of neurotoxicity is 
not clearly defined, and how to best manage these patients is 
also unclear. Rare cases of protracted neurotoxicity or death, or 
both, have been reported. The standardisation of a 
classification and grading system for cytokine release syndrome 
and neurotoxicity by Lee and colleagues,54 which is used in most 
studies, has helped to better characterise these adverse events. 
Yet the grading, especially for neurotoxicity, remains somewhat 
subjective and has room for improvement, and not all studies 
use the same grading system (The University of Pennsylvania 
has a separate grading system,55 whereas most other research 
groups use the Lee criteria). The FDA is testing the feasibility of 
keeping a safety database that pools safety information across 
multiple different investigational new drugs for CAR T-cell 
products.  The purpose of the database is to facilitate 
assessment of new safety information, and to inform 
regulatory advice to study sponsors to support the clinical 
development of their product (or products). Such pooled data 
might be important and similarly helpful for checkpoint 
inhibitors and CAR T-cell therapy.56 However, unlike with 
checkpoint-inhibitor therapy, the reporting of adverse events 
after CAR T-cell therapy is fairly accurate but is potentially 
overemphasised given the high-intensity but time-limited risk 
of this therapy on the one hand and the high clinical effect and 
efficacy on the other.57
With both therapies, however, reporting of adverse events after 
market approval becomes very important and is likely to fall short 
when these drugs and therapies are given to real-world patients. 
Such patients might have comorbidities that were either not 
included or were explicitly excluded in licensing trials, or might 
have received prior unexplored therapies potentially substantially 
changing adverse event risk and profile. Improved tools and 
strategies for post-marketing assessment and reporting of 
adverse events are necessary to fully understand the risk–benefit 
ratio and who should be receiving these therapies after the 
completion of a trial.
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part. Examples include thromboembolic disease with 
the use of lenalidomide50 and concerns with toxicity of 
steroids in patients with multiple myeloma.51 Patient 
advocates in the Eastern Cooperative Oncology Group 
in the USA identified high-dose steroids as a concern, 
leading to a randomised phase 3 trial51 in which low-
dose steroids with lenalidomide was found to improve 
survival in patients with multiple myeloma and a 
subsequent regulatory approval in the USA.
For the knowledge base of adverse event profiles to 
evolve for new medicines, real-time multidirectional 
information transfer between regulators, clinicians, and 
clinical investigators is required. For it to be impactful 
and to better protect patients in ongoing trials and the 
clinical setting, the information must be made available 
and must be accurate. The printed product label might 
no longer be the best method of transferring knowledge 
about adverse events in the 21st century. How data are 
presented can and should be much improved, and the 
goal should be real-time monitoring followed by accurate 
interpretive reporting.
Complexities of assessing adverse events that are 
unique to haematological malignancies
The definition of adverse events and challenges inherent 
in the analysis of adverse events, given the time profile 
of toxicities of existing and novel drugs, are common 
between haematological malignancies and solid 
tumours. However, specific features of haematological 
malignancies pose challenges to the assessment of some 
adverse events and warrant noting. For example, 
consider bone marrow involvement by tumours, a far 
more common situation in haema tological malignancies 
than in solid tumours. The grey area between bone 
marrow toxicity and the desired therapeutic effect 
complicates the reporting of adverse events and the 
interpretation of the aggregate data. The complex, 
supportive management of patients with marrow-
infiltrative disease must be balanced with treatment to 
avoid infections, bleeding complications, and other 
unavoidable adverse events brought on by disease or 
treatment. Navigating through these expected events 
might in some cases be the only avenue for potential 
cure of the underlying cancer. The grade 3 and 
4 haematological adverse events that commonly occur 
with acute leukaemias and aggressive lymphomas are 
not indicative of a therapy that is not effective or safe.
Another example of how interpretation of clinical and 
laboratory findings can be particularly challenging in 
haematological malignancies and have the potential to 
mislead drug development was seen during the develop-
ment of ibrutinib for chronic lymphocytic leukeamia. 
Immediate post-treatment leukocytosis could be inter-
preted as either a toxicity of the drug or as disease 
progression, when, in fact, it was the therapeutic effect of 
ibrutinib.52 Defining toxicities that qualify as dose-limiting 
toxicities is therefore challenging in these cases. Treatment 
of haematological diseases with HSCT also requires 
specific attention to the reporting of adverse events that 
differ from most solid tumour settings, and this will be 
addressed in section 4. Data collection of the adverse 
events is necessary, but the appropriate reporting must be 
made in the context of the disease under treatment.
The advent of immune therapies to treat a variety of 
haematological malignancies has also spurred challenges 
in adverse event assessment. Immune-related adverse 
events from checkpoint inhibitor therapy and CAR T-cell 
therapy, among others, are addressed in panel 2.
Ultimately, vast changes in treatment paradigms for 
haematological malignancies should spur changes in 
existing systems of adverse event assessment and a 
rethinking of early-phase and late-phase clinical trial 
designs, not only for acute toxicity but also for chronic, 
cumulative, and late adverse events (table 2). The 
ascertainment and reporting of adverse events would 
also be enhanced by inclusion of PROs.
Section 2: Incorporation of PROs in the 
assessment of adverse events
The welcome advances in outcomes with newer therapies 
for haematological malignancies are not without costs. 
There are challenges inherent to assessing the toxicities 
of prolonged, continuous therapies as part of daily life, as 
opposed to short-course cytotoxic therapy that have been 
the mainstay of treatment for many haematological 
malignancies for decades. The acceptable toxicities 
between these two different scenarios are probably 
different, and our understanding can be enhanced with 
the use of longitudinal PRO data. In this section, we 





• Implementation of longitudinal methods to assess chronic, 
low grade effects over time
• Analysis of chronic adverse event data in early phase trials for 
those patients receiving more than six cycles
• Area-under-the-curve analysis of adverse events from more 
than one trial to identify the optimal recommended 
phase 2 dose
• Assessment of a subpopulation of patients with chronic 
effects to identify effect
• Testing of different analytic approaches on existing trial data
• Retrospective 
assessment of trials in 
which chronic adverse 
events have been 
reported: prospective 
assessment 





• Use of data from multiple cycles to explore cumulative 
effects with dose modifications over time
• Assessment of cumulative effects of a given agent using 
adverse event data from more than one trial
• Inclusion of risk-based adverse event analysis for effects that 
are cumulative to account for patient attrition
• Retrospective 
assessment of trials in 
which chronic adverse 
events have been 
reported
• Prospective assessment 
accomplished in the next 
2–5 years
Improved analysis 
of late adverse 
events
• Necessitate long-term follow up on patients on trials where 
relevant
• Use of SEER and SEER-Medicare databases in the USA to do 
population assessment for late effects
• Build in the late follow-up for late effects in trials
• Inclusion of patient reported outcomes even later on or after 
a trial
• Retrospective analyses 
could start immediately
Table 2: Improving analysis and reporting of chronic, cumulative, and late adverse events
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focus on the use of PROs to enhance the understanding 
of toxicity in haematological malignancies.
Safety profiles of anticancer drugs are moving from a 
characteristic group of acute toxicities that recover 
between intermittent dosing, to potentially prolonged 
symptomatic side-effects that are heterogeneous in type 
and kinetics. These symptomatic adverse events might 
lead to dose modifications, elective patient discont-
inuation, or poor adherence to long-term treatment plans. 
They might also profoundly compromise a patient’s 
quality of life. The changing safety profile of cancer drugs 
has led to a call to rethink old practices and consider 
new methods to evaluate cancer product safety and 
tolerability.35 In addition to standard, routine clinical visits 
and clinician-reporting of adverse events, incorporating 
the patient in the assessment of cancer therapies is of 
great interest both in the clinical trial and clinical care 
settings.58
PROs, health-related quality of life, and PRO-CTCAE
PROs are assessments based on a report that comes 
directly from a patient about the status of their health 
without amendment or interpretation of their response 
by a clinician or anyone else.59 The term PRO is often 
confused with the term health-related quality of life. PRO 
is a broad term describing an assessment method, 
whereas health-related quality of life is a specific clinical 
outcome. In some cases, a clinical outcome might be 
assessed by various methods. For example, the clinical 
outcome of physical function can be measured by a PRO, 
a clinician-reported outcome assessment (eg, Karnofsky 
Performance Scale), or a performance outcome assess-
ment (eg, 6-min walk). Increasingly, there is also interest 
in the use of wearable devices to quantify a patient’s 
activity in daily life as a clinical outcome.
Health-related quality of life as a clinical outcome is 
assessed using a PRO measure. The outcome of health-
related quality of life is a multidimensional construct 
defined as the subjective perception of the effect of health 
(including disease and treatment) on physical, psycho-
logical, and social functioning and wellbeing.60 Typically, 
assessments of health-related quality of life in clinical 
trials are used to assess the effects of cancer and its 
treatment in aggregate on the patient’s perception of 
wellbeing. Such assessments provide a supportive 
outcome to complement the usual primary outcomes of 
disease control and overall survival.
The use of PROs in clinical trials can help to refine the 
understanding of patient benefit or harm when there are 
clear objectives for their inclusion. PRO assessments 
have provided important complementary information 
from the patient’s perspective on functional outcomes 
and the trajectory of symptoms over time.61 However, 
PRO assessments of generic measures of health-related 
quality of life or disease modules might not always 
incorporate the symptoms of interest for the diversity of 
novel therapies being investigated. Developers of 
commonly used PRO measures of health-related quality 
of life, such as the European Organisation for Research 
and Treatment of Cancer (EORTC),62 Functional 
Assessment of Chronic Illness Therapy (FACIT),63 and 
the EuroQOL 5D (EQ-5D)64 have developed standard 
disease modules, which are specific sets of questions 
assessing symptoms typically seen with the specified 
disease and side-effect profiles of some common, 
standard therapies. The questions included in these 
modules do not vary and do not have the flexibility to 
adjust to differing toxicity profiles seen with the wide 
range of drug classes in development for haematological 
malignancies. For instance, rash and ocular side-effects 
cannot be assessed with older generic tools. In addition, 
existing tools to measure health-related quality of life are 
often designed without assessing the burden and 
incentive of patients to provide meaningful data, further 
decreasing the validity of existing approaches to 
measuring health-related quality of life. Involving patient 
organisations in the development and validation of such 
tools could drive acceptability and data validity.
Increasingly, efforts have been made to overcome this 
lack of flexibility by incorporating additional ad-hoc 
questions about symptoms or side-effects to capture 
additional adverse events associated with the new 
treatments. Both EORTC and FACIT have publicly 
accessible item libraries of questions that allow physical 
symptoms to be selected to fit the context of the trial. 
This is a reasonable approach, but the symptom items in 
the generic forms might still include adverse events that 
are not typically expected to occur (eg, peripheral 
neuropathy in a trial with drugs with which that specific 
toxicity has not previously been recognised). Typically, 
health-related quality-of-life outcomes are reported as a 
summed score of the responses to each item. The 
addition of ad-hoc items would change the score and 
make it difficult to interpret the findings.
Although health-related quality of life and its functional 
domains (eg, physical, cognitive, emotional) can be 
affected by the toxicity of a therapy, there is increasing 
interest in specifically assessing symptomatic treatment-
related side-effects using PRO measures to complement 
clinical understanding of safety and tolerability. The NCI 
recently developed the Patient-Reported Outcomes 
version of the Common Terminology Criteria for Adverse 
Event (PRO-CTCAE) specifically for self-reporting of 
symptomatic adverse events, mapping to the well 
established CTCAE system for clinician reports. This 
item library for patients contains 124 PRO questions 
reflecting 78 symptomatic adverse events, which is 
derived from and designed to be used alongside standard 
clinical reported CTCAE assessments.65 PRO-CTCAE is 
flexible, such that applicable adverse events can be 
selected for admini stration depending on the expected 
side-effects of the given clinical trial. PRO-CTCAE 
has positive psychometric properties, including con-
struct validity, reliability, and responsiveness.65,66 With 
For PRO-CTCAE see https://
healthcaredelivery.cancer.gov/
pro-ctcae/
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PRO-CTCAE, patients score the different aspects of a 
symptomatic adverse event separately, such as the 
presence, frequency, severity, and activity interference 
associated with each term. PRO-CTCAE scores therefore 
do not correspond to clinician CTCAE grades. This 
difference permits the analysis of patient-reported 
interference separate from severity, which could lead to 
insights on tolerability.
PROs in existing haematological malignancies trials
Many clinical trials in patients with haematological 
malignancies have not typically incorporated health-
related quality of life or other PRO assessments. Data 
from NCI-sponsored clinical trials between 2004 and 
2016 show that less than 10% of the clinical trials with 
leukaemia, lymphoma, and myeloma patients have 
included PRO endpoints of health-related quality of life 
outcomes (table 3). Health-related quality of life 
endpoints were more likely to be assessed in myeloma 
phase 3 trials than in any other trial type.
Multiple myeloma is a chronic malignancy character-
ised by clinically significant symptoms related to disease 
burden (eg, bony pain, fatigue) and treatment toxicity 
(eg, neuropathy). In recent years, many newly approved 
drugs have improved outcomes in patients with 
incurable disease, with a shift from intensive induction 
therapy to a chronic delivery of therapy. Increasingly, 
PROs are being incorporated into clinical myeloma 
trials to assess the effect of treatment on health-related 
quality of life.67 Findings from two systematic reviews68,69 
showed that inclusion of health-related quality-of-life 
assessments in myeloma clinical trials is limited but 
increasing, and the analysis of these assessments 
showed substantial symptomatic improvement in 
health-related quality of life during first-line therapy. 
Inconsistencies in the incorporation and analysis of 
health-related quality of life in these trials, however, 
makes interpretation of these findings and cross-trial 
comparisons challenging.68
In addition to measuring a drug’s effect, PRO data can 
inform how patients are affected by their disease course. 
For example, the Eastern Cooperative Oncology Group 
(ECOG) incorporated longitudinal measurement PROs 
in the E4402 study70 comparing rituximab maintenance 
and retreatment strategy in patients with low-grade non-
Hodgkin lymphoma. The trial reported similar illness-
related anxiety, overall anxiety, and health-related quality 
of life between the groups. Investigators concluded that 
relapse might not be not associated with increased 
anxiety as previously thought, and the retreatment 
strategy resulted in similar patient outcomes while 
using fewer resources.70 The international phase 3 trial 
of watch-and-wait versus rituximab induction versus 
rituximab maintenance71 included health-related quality 
of life at 7 months as a primary endpoint. The rituximab 
groups had longer progression-free survival and time to 
chemotherapy or radiotherapy than those in the control 
(watch-and-wait) group, without difference in overall 
survival. The patients receiving maintenance therapy 
had improved mental adjustment to cancer scores 
compared with those on watchful waiting, although no 
difference was found in overall quality of life, anxiety, 
depression, or distress as measured by the Impact of 
Events-Scale.
Thus, use of health-related quality of life and other 
more defined PRO measures of patient function in these 
trials can provide additional information to understand 
the overall effect of the disease and treatment and brings 
the patient’s perspective into the treatment evaluation. 
However, the multidimensional construct for health-
related quality of life might not provide the specificity to 
understand what symptomatic toxicities could be driving 
the tolerability of a specific regimen.
Safety and tolerability
Safety and tolerability are crucial but capture different 
aspects of a regimen’s effect on patients. Safety is intended 
to reflect the medical assessment of an adverse event 
based on the clinician’s judgement about information 
such as medical history, physical examination, and 
laboratory and imaging findings. Tolerability reflects the 
extent to which overt adverse events affect the patient’s 
willingness and ability to continue the treatment regimen 
(figure 5; figure 6).72,73
As addressed in section 1, the primary method for 
assessing and reporting safety is clinician-graded 
adverse events based on the CTCAE that are reported in 
tables of the worst-grade events. These tables quickly 
and effectively communicate safety according to the 
numbers of patients who had the worst severity of 
toxicity at any point in time. However, the tables do not 
provide specific information about when the adverse 
events developed, resolved, or improved with supportive 
interventions, which are clinically relevant issues with 
Phase 1 Phase 1/2 Phase 2 Phase 3 Other Pilot Total
Leukaemia trials 1/49 (2%) 0/7 2/68 (29%) 5/11 (50%) 0/1 0/1 8/137 (6%)
Lymphoma trials 0/23 1/11 (9%) 6/63 (10%) 1/3 (33%) ·· 0/1 8/101 (8%)
Myeloma trials 0/5 1/4 (25%) 2/13 (15%) 7/11 (64%) ·· 0/2 10/35 (29%)
Data are number of trials with PROs/total number of trials (%). CTEP treatment trials (all phases) were activated between June 30, 2004, and Dec 31, 2016. 
In total, only 26 (10%) of 273 adult haematology clinical trials sponsored by the National Cancer institute had PROs. CTEP=Cancer Therapy Evaluation Program.
Table 3: Patient-reported outcomes (PROs) in 273 haematology adult trials sponsored by the National Cancer Institute
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Figure 5: Relevance of a time profile for adverse events
(A) Two grade 3 or higher adverse events with similar incidence associated with drug X and drug Y (as captured by 
conventional maximum grade reporting). (B) Conceptual example of a patient’s experience of adverse events 
associated with drug X and drug Y, demonstrating the relevance of time frame of different adverse events.  
Dyspnoea related to drug X peaks in severity and resolves within a few days, whereas neuropathy related to drug Y 
worsens steadily over time, having a different implication on tolerability of that regimen for the patient.


















Grade 3 or higher
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Peripheral neuropathy
Drug X plus standard regimen (n=463)
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the long-term, chronic, orally administrated drugs 
(or regimens). These aspects might be highly relevant to 
tolerability, even if they do not specifically affect safety. 
Novel graphical or analytical approaches (such as those 
presented in the last section) are necessary to incorporate 
the time profile of adverse events associated with several 
novel drugs.
Low-grade adverse events are not often the focus of 
safety assessments and might not be recorded on case 
report forms in many cancer trials. Whereas a low-grade 
change in potassium concentration might not be 
important to patients, low-grade symptomatic adverse 
events, such as nausea, diarrhoea, or neuropathy, can be 
burdensome to patients, particularly when chronic, or 
cumulative. Low-grade symptomatic adverse events have 
resulted in patient non-adherence to therapy.25,74–76 
Targeted therapies are often associated with a spectrum 
of non-specific adverse events that might not be frequent 
or severe but alter patient health-related quality of life.77 
Clinicians might underestimate the incidence and 
severity of symptoms relative to patients’ self-reports of 
similar information generated from PRO measures.78–80 
This difference in clinician and patient responses 
provides some of the distinction to illustrate the 
differences between safety and tolerability.81 A patient 
might have severe nausea that decreases food intake, but 
he or she is able to drink fluids and is not dehydrated. 
This patient would probably rate his or her nausea as 
severe; however, the clinician would categorise this 
nausea as grade 2 by CTCAE. Although a short course of 
treatment with the regimen causing this nausea might 
be tolerable for a few cycles, the drug is unlikely to be 
tolerable over months to years of treatment.
Understanding drug tolerability over time, such as by 
incorporating methods such as AUC evaluation for toxicity, 
as previously discussed, is essential to maximise patient 
benefit. Definitions of toxicity relative to drug exposure 
are helpful to clarify the time-related function of 
adverse events relative to drug exposure (panel 2). The 
inclusion of patient-reported symptomatic adverse events 
with tools such as PRO-CTCAE can provide additional data 
that is com plementary to safety data. PRO strategies 
should begin with a baseline assessment that includes 
longitudinal assessments throughout and at the end of 
treatment as well as multiple analytical and visualisation 
techniques.
Incorporation of health-related quality of life and other 
PRO measures to inform the patient experience while 
exposed to a cancer therapy can add value to our 
understanding of the effect of a new intervention. Efforts 
are underway to standardise how PRO measures can be 
analysed and presented.82,83 There is now growing interest 
in using item libraries such as the PRO-CTCAE to 
provide the needed flexibility to select the relevant 
emergent symptomatic adverse events for the trial 
context that can inform drug safety and tolerability in 
addition to measuring health-related quality of life.
Statistical analysis opportunities for PRO data
Standardising PRO assessment and analysis in cancer 
trials is crucial, and several international, collaborative 
efforts are underway in key areas to identify core outcome 
sets (eg, ICHOM,84 COMET85) standardised PRO 
analytical methods (SISAQOL),83 and standard PRO 
protocol elements (SPIRIT-PRO).86
Although development of a standardised approach to 
PRO statistical analysis is ongoing by SISAQOL, 
commonly used statistical analysis approaches to PRO 
data87 include: cross-sectional mean estimation with 
comparisons at key timepoints using t tests or analyses of 
covariance where the baseline PRO score is included as a 
covariate; longitudinal mean estimation with comparisons 
using generalised linear mixed modelling or generalised 
estimating equations; or summary measure approaches 
exemplified in the previous section (eg, AUC, responder 
definitions), with between-arm comparison using an 
applicable statistical comparison approach.
PRO data analysis should carefully handle missing data 
and multiplicity. The very best approach to handle missing 
data is to minimise its occurrence through thoughtful 
design and enhanced data collection and monitoring.88 
Figure 6: Safety and the patient experience to inform tolerability
CTCAE=Common Terminology Criteria for Adverse Events. PRO=patient-reported outcome.
Patient experience
• Patient-reported symptoms 
(PRO-CTCAE)
• Burden of treatment
Safety
• Clinician-reported symptoms 
(CTCAE)
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Reasons for missed reports should be captured during 
data collection and reported89 to understand how the 
missing data might bias results. The best statistical 
approach in the presence of missing data is a method that 
uses all available data and is robust to some types of 
missing data, followed by sensitivity analyses that employ 
a range of missing data methods (eg, generalised linear 
mixed modelling) to assess the robustness of results to 
various missing data assumptions. Multiplicity is 
commonly handled using a hierarchy approach where 
each PRO endpoint is identified as a primary, secondary, 
or exploratory endpoint. Other methods include alpha 
adjustment methods (eg, the Bonferroni method), 
resampling methods, or global tests (eg, O’Brien’s test). 
As is the case with CTCAE safety data, multiplicity is not a 
concern when PRO-based adverse event data are presented 
in a descriptive fashion without formal statistical 
comparisons.
Opportunities exist for developing optimal strategies 
for the estimation and visualisation of PRO-based adverse 
event data. PRO-based methods that typically rely on 
estimating severities (in trial participants in aggregate) 
might not adequately communicate findings to a clinical 
audience that is accustomed to standard adverse event 
reporting of percentages of patients with each CTCAE 
grade level. Summary approaches typically applied to 
CTCAE data might not adequately address missing PRO 
data issues or properly account for baseline symptoms. 
An alternative summary measure approach taking the 
baseline score into account90 mirrors how clinicians are 
trained to identify adverse events. If a symptom is present 
at baseline, then it might be considered an adverse effect 
if it worsens during treatment. Thus, in the proposed 
baseline adjustment approach, PRO-based adverse event 
scores that are the same as or improved from baseline are 
converted to a score of zero, and scores that are worse 
than baseline are analysed without modification. Taking 
baseline into account holds the potential to improve 
attribution of an adverse event to the drug under study—a 
particularly challenging issue in cancer trials with 
residual toxicities and cancer-related symptoms at 
baseline. Alternative methods that have yet to be fully 
explored for PRO-based adverse event data might include 
joint modelling of PRO-based adverse event data with 
CTCAE data or disease status, or both, or multiple 
imputation approaches that use clinician-based CTCAE 
data as auxiliary data.
Electronic collection of PROs
In addition to novel methods for analysis of PRO data, 
opportunities exist for improving collection of PROs in 
patients with haematological malignancies, both in the 
clinical trial setting and the practice setting. The 
traditional paper-based collection of PROs might be 
burdensome to patients and staff, particularly in the 
setting of inadequate resources and infrastructure. The 
telephone-based or electronic collection or PROs might 
ease some of these burdens by eliminating the need for 
printing, dissemination, and collection of questionnaires, 
manual scoring, and entry into a database. Electronic 
collection of PROs is reliable, valid, and might be 
preferred by patients.91
Despite the rapid uptake of electronic devices, from 
smartphones to tablets for entertainment, shopping, and 
banking, the incorporation of electronic PROs has been 
relatively slow in non-industry sponsored cancer clinical 
trials. There is a perception by clinical staff and trial 
investigators that patients, particularly elderly or frail 
patients, are unable or unwilling to use electronic 
devices. Yet findings presented in a recent Pew Report92 
show that roughly two-thirds of patients older than 
65 years use the internet, and more than 40% of this 
patient group has a smartphone. The rate of adoption is 
rapidly increasing, even as many senior patients 
acknowledge the need for additional help.
Patients with cancer are interested in PROs. The global 
patient organisation CML Advocates Network initiated 
an online survey in 63 countries to better understand the 
extent and drivers of non-adherence. More than 
2500 patients with chronic myelogenous leukaemia 
completed the web-based and paper-based survey, the 
results of which showed that adherence correlated with 
key factors that could be influenced through improved 
doctor–patient communication, such as management of 
side-effects and satisfaction with level of information 
about the disease. The survey noted that only 32·7% of 
patients with chronic myelogenous leukaemia were 
highly adherent to therapy, despite a clear correlation of 
adherence with therapy outcomes.25
With the widespread use of electronic medical records, 
it is now feasible to incorporate and display the patient 
self-reported disease symptoms and adverse events in the 
medical records. Yet many clinicians are reluctant to 
embrace electronic methods for collection of patient-
reported toxicity for a variety of reasons, including concern 
about data security, patient privacy and confidentiality, the 
potential to be overwhelmed with a large electronic 
workload, and clinical practice burden caused by potential 
need for clinical provider response to a patient-reported 
symptom or toxicity. These concerns are not insur-
mountable, particularly as evidence emerges to support 
the potential benefits in communication and management 
of symptoms in the clinical care setting.
Clinical trials to assess the integration of patient-
reported symptoms into routine care of patients with 
cancer have suggested that this approach can improve 
doctor–patient communication, result in better symptom 
control for individual patients, reduce patient distress, 
and have a positive effect on patients’ quality of life.93,94 
Electronic PRO collection of symptoms in patients with 
advanced malignancy has been found to improve health-
related quality of life, decrease emergency room visits, 
and increase survival, with greatest benefits reported by 
patients with the least computer experience.95
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Ultimately, electronic data collection enables the patient 
to report symptomatic adverse events in real time as they 
develop, which in turn allows early intervention with 
supportive medications. Further studies of the ease of 
workflow in clinics, acceptability by patients and 
providers, generalisability, and compliance will be 
necessary to understand the effect and implementation in 
both clinical trials and clinical care.96–98
Evolving treatment in many haematological malig-
nancies and the proliferation of chronically administered 
drugs in many different diseases have generated new 
challenges in understanding side-effects and how they 
affect patients. As therapy moves beyond a limited 
treatment window (for cytotoxics) to months or years 
with novel targeted drugs and immune therapies, 
tolerability will be just as integral as safety to the 
assessment of the drug. Incorporation of PROs into the 
assessment of adverse events holds great promise to 
inform our understanding of tolerability going forward.
Section 3: Special issues of toxicity from HSCT
In the preceding sections we have addressed the 
importance of how adverse events are defined, collected, 
and analysed and the rising need for PROs to enhance 
tolerability assessment. The focus of this subsection is 
adverse events of HSCT, a potentially curative procedure 
used to treat life-threatening malignant and non-
malignant haematological disorders. HSCT is a complex 
therapeutic approach that often involves administration 
of high doses of cytotoxic or immune suppressive drugs, 
or both. These drugs induce a myriad of toxicities, and 
HSCT is therefore a unique situation in toxicity assess-
ment in haematological malignancies. In this section we 
primarily discuss the challenges pertaining to the 
assessment of adverse events in HSCT in light of its 
multiple complex toxicities (including graft-versus-host 
disease in allogeneic HSCT), and we will propose how 
best to achieve consensus on which post-HSCT adverse 
events should be considered expected as a route to 
tackling this problem. We will subsequently also review 
adverse events related to HSCT-specific polymedication, 
infectious adverse events, and selected longer-term 
adverse events that arise after HSCT.
Challenges to assessing multiple complex toxicities in 
recipients of HSCT
Most HSCT recipients have at least one serious adverse 
event, and the overwhelming majority of patients will 
have more than one adverse event. Reporting the vast 
array of expected adverse events in the early HSCT setting 
is often cited as a barrier to clinical trials of drugs in 
HSCT. Attribution is difficult and sometimes impossible 
in the setting of multiple competing risks. Adverse events 
associated with HSCT include prolonged cytopenias and 
impaired innate and adaptive immune responses, leading 
to opportunistic infections, organ toxicity (particularly, 
although not limited, to the lungs, liver, kidney, and 
gastrointestinal tract), and therapy-related cancers. 
Toxicities are related to the conditioning regimen and can 
be affected by the inclusion of total body irradiation. 
Allogeneic HSCT involves infusion of genetically 
disparate grafts, with the potential for graft-versus-host 
disease, which can be life-threatening and necessitate 
prolonged immune suppressive therapy, contributing to 
the emergence of opportunistic in fections. Acute graft-
versus-host disease arises when donor graft immune cells 
recognise host tissue as foreign and injures the skin, gut, 
and liver. The Seattle99 and the International Bone Marrow 
Transplant Registry (IBMTR)100 grading systems are used 
to document the severity of acute graft-versus-host 
disease, despite some limitations.
The frequency of adverse events and the extent to 
which they are expected also makes under-reporting an 
issue in HSCT when guidance is not specific (other than 
the usual definition of serious adverse events) and when 
surveillance is not standardised. This is not only true for 
HSCT—in paediatric acute leukaemia, under-reporting 
of several organ toxicities has been found in automatic 
reviews of laboratory values through the electronic health 
record.101 However, under-reporting might be even more 
important for HSCT, where the importance of a particular 
adverse event in a specific setting or trial can only be 
ascertained by understanding its frequency in relation to 
what is expected.
Taking a so-called realistic approach, the Blood and 
Marrow Transplant Clinical Trials Network (BMT CTN), 
an American trials group supported by the National 
Institutes of Health (NIH), has developed a model where 
only unexpected grade 3–5 adverse events are reported in 
an expedited case-by-case manner, whereas all expected 
events are reported on calendar-driven case report forms. 
Independent medical monitors (typically transplant 
doctors or disease-matter experts) provide unbiased 
reviews of unexpected events or events that happen more 
frequently than expected. Additionally, estimations of 
expected rates of key toxicities that might be of particular 
concern, because of the drugs or strategies being tested, 
are defined in the protocol and monitored specifically 
with a sequential probability ratio test (SPRT), which 
allows the medical monitor and data and safety 
monitoring board to know when the observed adverse 
event occurs more often than expected. If the frequency 
falls outside the previously defined acceptable boundary, 
the SPRT rejects the null hypothesis and concludes that 
more events happen within the observed study time than 
predicted.
This so-called lean reporting process allows the BMT 
CTN to minimise the data reporting burden for centres, 
to ensure that all important toxicities are captured, and 
separate issues of real concern from background data. 
The approach was effective in the early detection of 
events that led to the closure of a trial of umbilical cord 
blood transplant from an unrelated donor for sickle cell 
disease, and the exclusion of busulfan-conditioning 
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regimens from a trial of sirolimus prophylaxis for graft-
versus-host disease after treatment of only eight and 
ten patients, respectively.102,103 This model is a far more 
effective than the one-by-one adverse event reports of 
common HSCT-related toxicities.
Fortunately, the field of HSCT is characterised by the 
existence of large national and international outcomes 
registries such as the Center for International Blood and 
Marrow Transplant Research (CIBMTR) and the European 
Society for Blood and Marrow Transplantation (EBMT), 
which systematically collect data on several toxicities that 
can aid in estimating expected rates and improving 
understanding of HSCT toxicity. These registries have 
similar functions, and bone-marrow transplant centres 
report to them. The CIBMTR systematically collects data 
on all recipients for 2 years after transplantation and 
attempts to maintain follow-up on patients through their 
transplant centres for as long as possible. Data are now 
available for more than 15 000 15-year survivors. The 
CIBMTR captures key clinical data entered by centres 
through an electronic data collection system but is limited 
in its scope because of funding constraints.104 Limitations 
to the large-scale registry include patient loss to follow-up, 
burden of data submission, and limited data on the patient 
perspective on quality of life and adverse events. 
Nevertheless, a particular strength of CIBMTR outcomes 
data is the reliability of identifying causes of death in the 
post-HSCT period (figure 7). These data serve as a guide to 
the likely serious adverse events encountered after HSCT 
and prevent biases that are specific to centres and drug 
regimens that are seen in the scientific literature.
In a similar manner, the EBMT is a voluntary organi-
sation of more than 500 transplant centres in  60 different 
countries (outside North America) that established a 
comprehensive transplant registry to collect outcomes 
data. Accreditation as a member centre requires sub-
mission of minimal essential data from all consecutive 
patients to the central registry, and patients can be 
identified by the diagnosis of underlying disease, type of 
transplantation, and transplant-related events. The EBMT 
registry enables detailed analyses of transplant-related 
complications and consequences, giving a real-life picture 
from many parts of the world. The EBMT and CIBMTR 
registries represent an unparalleled opportunity to refine 
the identification process of transplant-related toxicities. 
Although the safety and efficacy (ie, the estimate of effect 
under ideal circumstances) of a newly approved drug is 
usually first assessed in trials, post-regulatory appraisal 
relying on specific and comprehensive data collection 
from the registries will probably reveal clinical 
effectiveness and longer-term safety more efficiently 
(ie, the real-world effect).
Most international regulatory health authorities have 
grappled with the challenges of identifying drug-related 
toxicity in the context of numerous comorbidities and 
toxicity related to transplant or drug regimen. To help 
address these issues, we propose that the haematology 
community optimise their strategies and develop 
consensus on which post-HSCT adverse events should be 
expected, depending on graft source and transplant 
regimen, and on acceptably streamlined approaches to 
capture and analyse these adverse events so that 
unexpected increases in frequency can be detected 
without causing undue reporting burden to clinicians 
and research staff. Such a system should be evaluated 
and, we hope, advocated by regulatory authorities who 
have a key role in determining how trials are done, 
particularly in the corporate sector. Automated approaches 
to assessing data that are routinely captured in the 
electronic health record could potentially also help ensure 
complete reporting of adverse events.
Figure 7: Cause of death after haemopoietic stem-cell transplant (HSCT) from the Center for International 
Blood and Marrow Transplant Research, an example of valuable data from registries that catalogue toxicity 
and outcomes after HSCT
(A) Cause of death in first 3 years after allogeneic HSCT from 2008 to 2017. (B) Cause of death in first 3 years after 
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Polypharmacy and drug interactions as adverse events
In addition to its multiple toxicities with little consensus 
on what is expected, another challenge to toxicity 
assessment in HSCT lies in long list of concomitant 
medications that must be reported in traditional adverse 
event reporting systems. Polypharmacy is the rule 
for patients in the first few months (and sometimes 
longer) after HSCT. HSCT recipients receive complex 
drug regimens including cytotoxic drugs, immuno-
suppressants, antimicrobials, and sup portive and targeted 
therapies in many different combinations. The risk of a 
drug–drug interaction as an adverse event is therefore 
high. Most drug–drug interactions in HSCT alter the 
concentration of the drug in the body, and they occur most 
often in the gut and liver and involve cytochrome P-450 
(CYP450)-mediated metabolism, inhibition, or induction.105 
For example, fluconazole is a moderate inhibitor of 
CYP3A4, whereas posaconazole is a strong inhibitor; these 
drugs therefore both affect metabolism of tacrolimus and 
sirolimus (both of which are CYP3A4 substrates).106,107 
Relatively benign drugs such as non-absorbable oral 
steroids can also trigger CYP-mediated interactions that 
are toxic.108 Genetic polymorphisms further complicate 
potential CYP interactions, and the frequencies and types 
of interactions are highly variable in different ethnic 
groups.105,106 Checking for CYP polymorphisms in patients 
who show signs of unusual drug metabolism without 
other identifiable causes is important.
Pharmacodynamic interactions due to the physiological 
activity or effects of a drug are also important. For 
example, the incidence of thrombotic microangiopathy is 
higher when tacrolimus and sirolimus are used in 
combination (10–15%) than when each drug is given 
alone (<5%).109 Some of the most frequent pharma-
codynamic interactions in HSCT are QTc prolongation 
and myelosuppression, common adverse effects of many 
of the drugs used in HSCT. These types of drug 
interactions should therefore be considered when 
initiating medications, and the patient should be 
monitored for adverse events that are potentially related 
to pharmacokinetic or pharmacodynamic alterations.
Infectious adverse events
Infectious complications are common after HSCT and 
are difficult to characterise and report as adverse events. 
Different patterns of infection happen at different times, 
and the risk and type of infectious syndrome varies 
according to time after transplant and to severity and type 
of immune compromise.110,111 Infectious complications 
often happen with or after other non-infectious com-
plications, particularly those that compromise tissue 
barrier function in the host (eg, oral or gastrointestinal 
tract mucosa) and impede immune reconstitution. The 
risk for infectious adverse events can therefore only be 
interpreted in the context of other toxicities.
The severity of infectious adverse events is also difficult 
to categorise. To date, only one severity grading system in 
HSCT recipients has been validated with survival,112 but 
this scoring system has limitations. Both severity of 
infection and resource use, such as the need for more 
complicated therapies (intravenous antimicrobial therapy 
or hospitalisation), were used to drive grading. Although 
satisfactory more than a decade ago, many therapies have 
become oral in the past decade or are now routinely 
managed in an outpatient setting, making the current 
scoring system no longer suitable. Moreover, the scoring 
algorithm did not include several infectious complications 
that now occur. To address these limitations, the BMT 
CTN developed a severity algorithm to monitor infectious 
adverse events in its clinical trials,113 but it has not been 
validated with survival.
Ascertainment biases in measuring infectious risk are 
common in HSCT trials. Two common sources of bias are 
unfamiliarity with infectious disease definitions and lack 
of complete diagnostic assessment. Lack of familiarity 
with infection definitions often leads to over-estimates of 
certain infectious complications. By contrast, incomplete 
diagnostic assessment frequently leads to underestimation 
of other infections and relies unduly on empirical 
antimicrobial therapies (ie, antimicrobial therapies used 
presumptively, without a clear definition of the source of 
infection). The aggressiveness of diagnostic assessment 
varies between centres, making cross-centre comparisons 
difficult. Moreover, differences in antimicrobial practices 
can affect the rates and types of infections. Findings from 
several studies emphasise the need for audits of data 
reports by experts who are knowledgeable in the diagnostic 
criteria.114
The above considerations highlight existing challenges 
in the assessment of infectious adverse events. Validation 
of a modern severity algorithm is a priority. In studies 
where infectious adverse events are primary endpoints or 
important secondary endpoints, specific training of study 
personnel at study sites and external auditing of data 
reports are important for accurate assessment of adverse 
events. Additionally, standardisation of diagnostic 
assessment strategies and antimicrobial use is important 
to reduce inter-centre variability.
Sexual dysfunction and infertility
Sexual dysfunction and fertility issues are to be considered 
among the serious adverse events after HSCT and in 
survivors of some haematological malignancies who did 
not undergo transplant. Sexual dysfunction in the form of 
body image problems, lack of sexual desire, and impaired 
physical functioning are common soon after HSCT.115,116 
These common problems can last for up to 10 years after 
transplant in female survivors, whereas men are more 
often able to return to baseline sexual function a few years 
after transplant.117 Sexual dysfunction as a post-transplant 
adverse event is often underdiagnosed and underreported, 
in part because of the lack of a specialised team in sexuality 
at most transplant centres. Only 20–50% of patients have a 
discussion with their doctors about sexual health after 
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HSCT.118 The use of self-reported and validated sexuality 
questionnaires, such as the 37-item Sexual Function 
Questionnaire or other patient-reported out come forms, 
can help to identify and grade sexual dysfunction after 
transplant.116,119,120 However, the use of different question-
naires between studies makes attempts at comparing 
results problematic. The development and validation of a 
tool combining PROs and gradation of adverse events is a 
priority to help to identify the timing and risk factors of 
post-HSCT sexual dysfunction and enable the develop-
ment of preventative strategies.
Myeloablative therapy (such as high-dose total-body 
irradiation or high-dose busulfan-based regimen condi-
tioning regimens) after HSCT is often associated with 
azoospermia and premature ovarian failure.121,122 There 
challenges are inherent to the study of fertility after HSCT, 
although the rate of pregnancy in survivors or in survivor 
partners has been assessed in a few studies and found to 
be less than 10%.123–125 Potential biases in these studies 
include lack of systematic paternity testing in female 
partners of male patients and the likelihood that successful 
rather than unsuccessful pregnancies are reported. 
Implementing consultative mechanisms for fertility 
preservation before treatment and family planning during 
and after cancer has been an important priority raised by 
patient advocacy organisations.
Although important progress has been made in 
fertility medicine as less toxic conditioning regimens 
are increasingly used, prospective data on fertility 
and pregnancy outcomes in HSCT survivors and their 
partners are needed.126
Neurocognitive impairment
Impairment of neurocognitive function is increasingly 
recognised as an important adverse effect and can be seen 
within the first 100 days after HSCT and up to 10 years 
later or more. Up to 50% of transplant recipients can be 
affected by neurocognitive impairment.127 Functions 
subject to impairment include memory, verbal recall, 
multitasking, coordination, motor dexterity, and speed. 
Although a global deficit score has been used, a consensus 
standardised scoring system requires confirmation and 
itemisation and might have to factor in the time after 
HSCT (ie, acute events within 100 days vs dysfunction 
during the medium term [2–5 years] and long term 
[>6 years]). A consensus panel to address these issues is 
encouraged.
Secondary malignancies after HSCT
Different categories of secondary malignancies that can 
occur after HSCT include post-transplant lympho-
proliferative disorders, donor-type secondary leukaemia 
(or other malignancy), and de-novo solid tumours.128 
Total-body irradiation and the chemotherapeutic drugs 
used before HSCT as part of the conditioning regimen 
can induce new secondary malignancies after HSCT. This 
is attributed to the mutagenic risk of irradiation and 
chemotherapy, the genetic predisposition of the patient to 
develop cancer, prolonged immunosuppression, and to 
age-related risk (in elderly patients). Secondary malig-
nancies after HSCT are another example of the myriad of 
toxicities that challenge conventional toxicity reporting. 
The many issues pertaining to assessment of adverse 
events in HSCT, as well as potential solutions and 
timelines for action, are summarised in table 4.
Section 4: Survivorship and long-term toxicity 
in haematological malignancies
Long-term toxicities such as neurocognitive impairment 
and sexual dysfunction affect not only patients who have 
undergone HSCT but survivors of other haematological 
malignancies. In this section, we focus on challenges in the 
assessment of adverse events in survivors of haematological 
cancers. 15·5 million individuals in the USA have a history 
of cancer, and this number is expected to increase to 
20·3 million by 2026.129 Long-term toxicity, or late adverse 
effects, in cancer survivors result from subclinical or 
asymptomatic physiologic changes that do not cause 
immediate, intermittent, or short-term clinical events but 
that, with extended time (many years or even decades), 
develop into clinically manifest adverse effects. These late 
effects can substantially affect morbidity, mortality, and 
quality of life and thus are crucial considerations when 
assessing survivorship in haematological malignancies.
Heterogeneity of late effects in survivors of 
haematological malignancies
The marked heterogeneity among survivors of haema-
tological malignancy necessitates a highly individualised 
approach to understanding the risk of late effects. 
Key determinants of late effects include treatments 
administered to cure or control the disease, patient-
related factors, and the underlying disease.
Proposed solutions: more research 
and immediate action
 Timelines
Improve post-HSCT data 
capture, analysis, and 
evaluation
Engage haematology and 
bone-marrow transplant 
communities to reach consensus on 
expected adverse events post-HSCT
Convene consensus conference of 
stakeholders for early 2019 and 
provide consensus document in 2020
Improve assessment of drug 
interactions
Investigate availability of CYP 
polymorphism status of drugs used 
post-HSCT
Provide report by mid 2019
Update severity of infectious 
disease algorithm
Convene infectious disease and 
bone-marrow transplant 
stakeholders to develop consensus
Consensus meeting in early 2019; 
draft consensus document available 
2020
Enhance data capture and 
grading of sexual 
dysfunction and infertility
Convene consensus conference on 
combined tool to report outcomes 
and grading of adverse events
Plan consensus conference for late 
2018, and consensus report in 2020
Improve neurocognitive 
studies post-HSCT
Encourage critical reviews of area Plan consensus conference on 
standardisation of grading of 
neurocognitive adverse events for 
2020
Table 4: Improving assessment of adverse events in haemopoietic stem-cell transplantation (HSCT), by 
priority area
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Treatments are typically considered the most important 
contributor to the development of late adverse effects. For 
highly curable diseases such as Hodgkin’s lymphoma, 
greater emphasis is now placed on selecting initial 
treatments to maximally avoid late effects. For more 
aggressive diseases or diseases with greater risk of relapse, 
higher intensity treatment with a curative goal in the near-
term is usually considered more important than the long-
term potential for adverse effects. A new challenge is the 
long-term management of a range of haematological 
malignancies such as chronic myelogenous leukaemia, 
chronic lymphocytic leukaemia, indolent lymphoma, and 
hairy cell leukaemia, which are generally considered 
incurable but can now be associated with patient survival 
for decades. These diseases now require continued focus 
on treating the inevitable relapses of the underlying 
malignancy and potential late effects. These challenges 
are further confounded by the relatively recent application 
of new therapeutic classes of targeted drugs, for which 
data on potential late effects are only beginning to emerge.
Patient-related factors also affect toxicities in survivors 
of haematological malignancies, either acting jointly 
with specific treatment exposures or independently of 
treatment. These can be intrinsic factors (eg, age at 
diagnosis, sex, inherited genetic susceptibility) or lifestyle 
and medical history factors (eg, cigarette smoking, 
obesity, exercise). Age at diagnosis is the most established 
patient-related factor that affects risk for late adverse 
effects. Long-term toxicities are of particular concern for 
individuals diagnosed at young age because of the 
potential for increased susceptibility to adverse effects of 
treatments and the decades of survival during which 
patients might experience effects. Some specific issues of 
concern for young survivors include pubertal develop-
ment status at treatment and risk of late infertility, the 
interaction between anthracyclines and age at exposure 
on subsequent cardiovascular disease,130 the modulating 
effect of age and breast radiation exposure on the risk of 
second breast cancer,131 and the devastating effect of 
childhood radiation therapy on subsequent muscle and 
bone maturity.
The disease itself can be an important determinant of 
long-term toxicities, as some haematological malignancies 
are intrinsically associated with future disorders. 
Examples include the strong relationship between several 
lymphoid malignancies and subsequent melanoma and 
non-melanoma skin cancer132 and the increased 
propensity of long-term survivors of chronic lymphocytic 
leukaemia to develop infections.
Late effects in survivors of haematological malignancies
Many potential late effects can affect survivors of 
haematological malignancies. We will discuss three broad 
categories: second malignancies, cardiovascular disease, 
and psychosocial impairments.
The development of second malignancies is a major 
contributor to morbidity and mortality in survivors of 
haematological malignancies.133,134 Large-scale, population-
based cancer registry studies have quantified specific 
patterns of risk, which vary substantially for survivors of 
different types of haematological malignancies. However, 
substantial additional research is needed to discover key 
risk factors, which can then inform long-term follow-up 
guidelines to screen for second malignancies.
Patients with Hodgkin’s lymphoma, the most studied 
group of haematological malignancy survivors, are at 
least three-fold to five-fold increased risk of developing 
subsequent malignancies in or near the radiotherapy 
field. Indeed, the risk of death from second primary 
malignancy exceeds that of death from the lymphoma 
itself.135 For cancers of the breast, thyroid, lung, 
oesophagus, stomach, pancreas, and colon, the risk of 
death follows a linear dose-response where risk increases 
with increasing radiation dose.136 Some classes of cytotoxic 
chemotherapy also increase the risk of subsequent 
cancers, including myelodysplastic syndrome and acute 
myeloid leukaemia.133 Reductions in radiotherapy doses 
and volumes of tissue irradiated as well as the shift to less 
marrow-damaging chemotherapy regimens (eg, from 
mustine, vincristine, procarbazine, and prednisone 
[MOPP] to ABVD) to treat Hodgkin’s lymphoma are 
expected to reduce the risk for subsequent malignancies, 
but long-term follow-up of patients that have been treated 
recently is needed to confirm this expectation.
Survivors of other haematological malignancies are also 
at increased risk of developing subsequent malignancies. 
Risks of chemotherapy-related myelo dysplastic syndrome 
and acute myeloid leukaemia are increased for survivors 
of nearly all haematological malignancies.137 With the 
introduction of targeted therapy and the shift toward an 
era of oral chronic therapy, monitoring risks associated 
with novel approaches to systemic therapy will be pivotal. 
Risks for lung cancer and melanoma after chronic 
lymphocytic leukeamia or small lymphocytic lymphoma 
are higher than for survivors of other types of 
haematological malignancies, probably because of long-
term immune dysfunction.138 Non-treatment risk factors 
for subsequent neoplasms are also being evaluated. 
Substantial advances in genomics in the past decade hold 
potential promise for future studies to comprehensively 
evaluate shared genetic contributors to several types of 
malignancies and to identify genetic susceptibility to 
treatment-related neoplasms.139 Other major cancer risk 
factors (eg, cigarette smoking, obesity, and alcohol) also 
probably contribute to the occurrence of subsequent 
neoplasms, although these patterns of risk might be 
similar to those of the general population.
Cardiovascular disease is increasingly recognised as 
one of the leading causes of morbidity and mortality 
among survivors of certain haematological malignancies. 
A substantial amount has been learned from studying 
the long-term health of survivors of Hodgkin’s lymphoma 
who often receive both chest radiotherapy and anthra-
cyclines.140 Risks vary by the specific type of cardiovascular 
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disease, emphasising the importance of detailed clinical 
data. Specifically, increasing dose of radiation to the 
chest, which exposes the heart to larger radiation doses, 
is associated with increasing risk of coronary heart 
disease, valvular heart disease, congestive heart failure, 
and pericarditis, with risks first evident 5 years after 
treatment and persisting for decades. By contrast, 
anthracycline-containing chemo therapy is associated 
with congestive heart failure, with risks sometimes 
becoming evident during treatment and persisting for 
decades. Importantly, the true magnitude of risk is 
probably underestimated in most previous studies 
because a substantial number of survivors might have 
had some degree of unrecognised and asymptomatic 
cardio vascular impairment.141
Compared with the general population, survivors of 
haematological malignancies have an increased risk of 
psychosocial issues, including depression, somatic 
distress, anxiety, and post-traumatic stress disorder.142,143 
Employment is often affected during cancer treatment, 
and changes in work roles often persist long into 
survivorship. The economic burden of cancer can persist 
for years after diagnosis.144 In addition to the issues 
experienced by cured survivors, many patients with 
haematological malignancies have chronic malignancies 
(eg, chronic myelogenous leukaemia, follicular 
lymphoma), which might create unique anxiety and 
uncertainty issues. Development of late medical 
complications of therapy and psychosocial issues are 
associated with a reduced quality of life.145,146
Call to action for survivor care: infrastructure and 
health-care delivery
A challenge clearly exists: there is marked heterogeneity 
in survivors of haematological malignancies, and the 
potential late adverse effects are numerous. To satis-
factorily capture adverse events in survivors, we identify 
two areas of unmet needs: infrastructure and health-care 
delivery.
Quantifying risks of long-term toxicity in survivors of 
haematological malignancies will rely on substantial 
efforts to develop infrastructure for systematic data 
collection over an extended period of time and across the 
multiplicity of health-care settings traversed by the 
patient. Focused institutional studies with intensive data 
collection provide detailed insights into long-term 
toxicities, whereas large-scale linkage studies provide 
more population-based information on larger groups of 
patients, albeit with less detail. Several ongoing efforts 
exemplify the tremendous promise and the challenges in 
collecting data necessary for long-term follow-up studies 
using different strategies.
Two ongoing patient cohorts exemplify the more 
intensive data collection that also includes direct patient 
contact. The Childhood Cancer Survivor Study (CCSS)147 is 
a retrospective cohort of more than 30 000 5-year survivors 
of childhood cancer diagnosed during 1970–99 from 
31 institutions in the USA and Canada. Detailed data on 
disease characteristics and treatments occurring within 
the first 5 years after childhood cancer diagnosis are 
transferred onto standardised forms at participating 
institutions. Vital status is updated through periodic 
linkage with the National Death Index in the USA, 
whereas other detailed information on a wide range of 
medical conditions is collected through self-report from 
patient questionnaires. The Lymphoma Epidemiology of 
Outcomes Cohort Study is a prospective cohort study of 
more than 12 000 patients with non-Hodgkin lymphoma 
who were diagnosed at one of seven centres in the USA. 
Similar to the CCSS, data are derived both from medical 
records and patient questionnaires. These cohorts provide 
the tremendous benefit of capturing detailed long-term 
toxicity data from patients with haematological 
malignancies in a systematic way, but the resource-
intensive nature of this approach is not feasible for all 
patients. Limitations to the large-scale cohort or registry 
include patient loss to follow-up, burden of data 
submission, and limited data on the patient perspective 
on quality of life and adverse events. However, additional 
cohort studies and registries must be encouraged to 
provide insight into long-term outcomes of patients with 
other haematological malignancies and receiving a broad 
range of therapies.
In addition to improving infrastructure to document late 
toxicities, long-term survivors of cancer are in need of 
coordinated care that goes beyond surveillance for 
recurrence. A risk-stratified approach to care, where 
health-care services are based on risk of recurrence and 
risk of late effects, has been advocated.148 The most 
intensive approach is a multidisciplinary survivorship 
clinic, which is generally limited to academic medical 
institutions and reserved for patients at high risk of serious 
late effects such as patients with Hodgkin’s lymphoma 
who were treated with intensive regimens before 2000 and 
those patients who have undergone HSCT. Patients at low 
risk of late effects can be followed by their primary care 
provider. Many survivors fall into the moderate risk 
category, where shared care between the haematology–
oncology team, primary care team, and perhaps 
survivorship team, is recommended. However, few studies 
have compared outcomes, specifically identification of 
adverse events, between these different models.
Given limitations in the present reach of multi-
disciplinary survivorship clinics, attention has been 
focused on survivorship care plans (SCPs) as a tool to 
promote coordinated, high-quality survivorship care. 
SCPs offer the promise of promoting patients’ 
understanding of their illness, treatment received, risks 
of late effects, and ability to seek out appropriate 
surveillance preventive health care. However, despite 
repeated calls for increased use of SCPs from the 
Institute of Medicine, broad implementation of SCPs 
into routine practice has not been achieved.149 Limitations 
to more broad adoption include: logistical challenges 
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because preparing an individualised, evidence-based 
SCP is time-consuming and non-reimbursed activity; 
and scientific shortcomings because few high-quality 
randomised trials have been done to assess patient-level 
effect of SCPs, and the benefits have not yet been 
definitely demonstrated in trials.150 Despite these 
barriers, implementation of SCPs has become a 
component in the cancer centre quality review and 
accreditation processes. Better integration of SCPs 
within electronic health records could that improve the 
tailoring of survivorship care,151 and education of 
haematology–oncology doctors in communication skills 
inherent to the survivorship transition for survivors,152 
are two possible approaches to enhancing the effect of 
SCPs on the wellbeing of survivors of haematological 
malignancy. Ultimately, evidence-based guidelines for 
optimal long-term follow-up care of patients are needed.
In conclusion, there are a burgeoning number of 
survivors of haematological malignancies, with hetero-
geneity in patients, diseases, and treatment. Adverse 
events in these patients could include second malignancies, 
cardiovascular disease, and psychosocial issues. Improve-
ments in infrastructure and health-care delivery are 
essential to improve understanding of late toxicities and 
long-term health of these patients.
Section 5: Adverse events in haematological 
malignancies and regulatory approval
Traditional reporting of adverse events: pre-approval
Although broadly applicable across all malignancies, an 
understanding of international regulatory processes and 
challenges inherent to the approval of new cancer drugs 
is vital to improving processes of adverse event evaluation 
in haematological malignancies and constitutes the focus 
of this subsection. Although regulatory bodies of 
different countries differ with regard to nuanced details 
of the regulatory process, there are many similarities 
between the way the FDA, European Medicines Agency 
(EMA), Australian Therapeutic Goods Administration 
(TGA), and Japanese Pharmaceuticals and Medical 
Devices Agency (PMDA) have traditionally dealt with 
toxicity assessments before drug approval (table 5). Each 
regulatory body has basic requirements for reporting 
adverse events that cross a certain qualitative or 
quantitative threshold. In the USA, sponsors must 
immediately report serious, unexpected, and suspected 
adverse reactions that occur on a trial that is done under 
an investigational new drug application.153 These 
regulations were amended in 2010 by the final rule 
requiring periodic review of aggregated safety data to 
ensure detection of new safety signals or a higher rate of 
serious suspected adverse reactions.154
In the European Union (EU), the clinical trial sponsor 
is responsible for recording adverse events, reporting 
serious, unexpected, and suspected adverse reactions to 
the national competent authority (directly or through 
the Eudravigilance Clinical Trials Module; EVCTM) and 
the ethics committee, and reporting safety data to the 
national competent authority and the Ethics Committee 
on an annual basis.155 The PMDA in Japan and TGA in 
Australia also require that at least unexpected fatal or life-
threatening adverse events occurring on clinical trials in 
those countries be reported to each agency.
Although international regulation has been successful 
in fostering the safe development of therapeutics, 
harmonisation and adherence to regulation of 
international clinical trials must be improved. Minor 
differences in requirements between regulatory bodies 
mean that individual agencies receive data at different 
times, potentially leading to variation in the risk–benefit 
assessment at any given time. Moreover, only 14% of the 
reports submitted to the FDA Office of Haematology 
Oncology Products in 2015 were considered infor mative.156 
The so-called noise of unnecessary safety reports 
potentially masks the true safety signals that this reporting 
is intended to detect. Submission of these reports 
introduces inefficiencies that prevent detection of useful 
toxicity data that can inform further clinical development 
and regulatory decision making. The time and financial 
resources required of already burdened investigators, 
nurses, and clinical research professionals serve as 
additional motivation to streamline safety reporting.
Limitations in safety reporting in the premarket setting 
are widely recognised. Inefficiencies in reporting 
requirements could lead to the reporter fatigue bias in 
reporting of adverse events that is generally seen in 
medical publications, and in haematology and oncology 
trials in particular.157,158 The reliability of toxicity data is 
further limited in the premarketing setting because 
safety reports are submitted on an individual basis rather 
than in aggregate. When submitted in aggregate, safety 
data are analysed as tabulations of severe or grade 3–4 
all-causal ity adverse events, and some categories might 
not be equally informative about product safety.159 
Measures of tolerability (eg, drug interruptions and 
discontinuations or dose reductions) and PROs might 
not be captured.160–162 Health-care utilisation (ie, hospi-
talisations, con comitant medications) administered to 
treat toxicity could be better documented. Trial 
populations are often younger or healthier than those 
with the disease in the general population.163 Gaps in our 
understanding of a product’s safety and tolerability at the 
time of approval behoove us to enhance post-marketing 
surveillance to complement other safety and tolerability 
assessments and better understand the product’s use in a 
real-world population.
Safety review of a submitted marketing application
The standard required for approval across regulatory 
agencies is demonstration of safety and effectiveness. 
The safety analysis that informs the risk–benefit 
assessment relies heavily on the use of tabulated rates 
of severe and high-grade adverse events, with some 
weight given to dose interruptions, discontinuations, 
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and reductions. Increasingly, approval is granted on the 
basis of surrogate endpoints collected earlier in the 
drug development process (accelerated approval in 
the USA, conditional marketing authorisation in 
the EU, con ditional and term-limited approval in Japan, 
etc), allowing earlier patient access to promising new 
therapeutic agents.164,165 Approval based on endpoints 
occurring well before death reduces the duration of 
administration and follow-up compared with ran-
domised trials using survival endpoints. Unlike many 
cytotoxic drugs given intermittently and for relatively 
short durations, toxicities seen with chronically 
administered, targeted drugs can vary in onset, 
duration, and character, as previously discussed. 
Adverse drug reactions could be idiosyncratic or related 
to cumulative toxicity, and the shorter trial duration and 
follow-up characteristic of approvals using expedited 
regulatory pathways limits characterisation of the 
intermediate and long-term safety profile for these 
drugs. Furthermore, the predominance of single-arm 
trials using expedited pathways challenges accurate 
attribution of an adverse event to the therapy. 
In haematology–oncology, differen tiating adverse 
events related to the cancer or other comorbidities from 
those that are potentially drug-related is particularly 
challenging.
USA EU Japan Australia
Form Centralised; reporting to FDA Decentralised; reporting to competent 
authority of each member nation or their 
authorised surrogate
Centralised; reporting to PMDA Centralised; reporting to TGA
Agency FDA: full authority (including withdrawal 
and approval of products)
EMA: operates the system on behalf of 
the EU medicines regulatory network; 
responsible for signal management of 
centrally authorised medicinal products in 
collaboration with PRAC assessor
PMDA and MHLW: full authority 
(including withdrawal and approval of 
products)
TGA: full authority (including 
withdrawal and approval of products)
Adverse event 
compilation
FAERS (currently only post-approval; 
pilots of pre-approval safety); Sentinel 
post-approval*
Eudravigilance database pre-authorisation 
and post-authorisation
JADER/MID-NET post-authorisation EPMMA post-authorisation
Expedited safety 
reporting: attribution
Only events suspected to be drug-related Events suspected to be related to 
investigational drugs, including events 
related to placebo
Only events suspected to be drug-related Only events suspected to be 
drug-related
Expedited safety reporting timelines
Pre-approval Fatal or life-threatening adverse events 
within 7 days; Alert Reports of serious and 
unexpected adverse events within 15 days
Fatal or life-threatening SUSARs within 
7 days; Alert Reports of serious and 
unexpected adverse events within 15 days
Unexpected and fatal adverse events 
within 7 days; serious and unexpected 
adverse events and expected and fatal 
adverse events within 15 days
Unexpected and fatal adverse events 
within 7 days; serious and unexpected 
adverse events and expected and fatal 
adverse events within 15 days
Post-authorisation Alert Reports of serious and unexpected 
adverse events within 15 days
Individual case safety report within 15 days 
for serious EEA and non-EEA cases and 
within 90 days for non-serious EEA cases 
(as of Nov 22, 2017)
Serious and unexpected adverse events 
and expected and fatal adverse events 
within 15 days or 30 days; serious and 
expected adverse events within 30 days
Serious and unexpected adverse events 
and expected and fatal adverse events 
within 15 days; serious and expected 
adverse events within 15 days or 30 days
Periodic adverse event and safety updates
Pre-approval Annual development safety update 
report†
Annual development safety update report Annual development safety update 
report
Periodic safety update report
Post-approval Periodic adverse drug experience report; 
periodic adverse experience report
Periodic safety update report Periodic benefit-risk assessment report Periodic adverse event and safety 
updates
Submission frequency Annual development safety update 
report; periodic adverse drug experience 
report or periodic adverse experience 
report quarterly for the first 3 years and 
yearly thereafter
Annual development safety update report; 
periodic safety update report every 
6 months after product authorisation, 
every 6 months for 2 years after marketing, 
yearly for the following 2 years, and 
every 3 years thereafter (depending on 
each member nation)
Annual development safety update 
report; periodic benefit-risk assessment 
report every 6 months for 2 years after 
marketing, yearly for following years 
during the re-examination period 
(10 years for orphan drugs, 8 years for 
new molecular entity drugs, and 4 years 
or 6 years for the other drug applications)
Every 6 months after product 
authorisation, every 6 months for 
2 years after marketing, yearly for the 
following 2 years, and every 3 years 
thereafter
Content Narrative summary of the information in 
the report and an analysis of the 15-day 
Alert Reports
Individual case safety reports not 
included; all adverse event data submitted 
directly to EudraVigilance database
Analysis, summary table, and case list 
included; individual case safety reports 
not included
··
EU=European Union. FDA=US Food and Drug Administration. EEA=European Economic Area. EMA=European Medicines Agency. EPMMA=enhanced post-marketing monitoring and analytics. FAERS=FDA 
adverse event reporting system. IND=investigational new drug. JADER=Japanese Adverse Drug Event Report database. MHLW=Ministry of health, labour and welfare. PMDA=Japanese Pharmaceuticals and 
Medical Devices Agency. PRAC=Pharmacovigilance Risk Assessment Committee. SUSAR=suspected unexpected serious adverse reaction. TGA=Australian Therapeutic Goods Administration. *The Sentinel 
database is composed of health outcomes; it might be used to identify outcomes of interest which could be potential adverse events or to establish so-called background occurrences of specific medical 
conditions or drug utilisation patterns, or both. †IND safety reporting requirements include submission of aggregate analyses of specific events (21CCFR 312.32©(1)(i)(C). The IND annual report must include a 
summary of the safety reports submitted during the past year and must include specific details such as most frequent and most serious adverse events, causes of death, and dropouts associated with any adverse 
event; the development safety update report can meet these annual reporting requirements.
Table 5: Global approaches to adverse event reporting
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To mitigate these uncertainties, regulatory agencies 
leverage post-marketing pharmacovigilance and clinical 
studies. The FDA has the authority to require or request 
further studies to better characterise safety after the 
approval of a drug.166 These studies assess or identify a 
serious risk (or risks) related to the use of a drug but are 
subject to the same challenges with respect to toxicity 
reporting in clinical trials. The TGA also mandates 
standard and non-standard post-marketing requirements 
after approval, and the PMDA can mandate post-
marketing investigations during the re-examination 
period. At the time of finalising a procedure or in 
follow-up of a signal evaluation, the EMA’s committee 
(or committees) might indicate that a risk-management 
plan with additional pharmacovigilance activities be 
provided. This includes the ability to impose a legal 
obligation to conduct a post-authorisation safety study.167
Efforts to improve safety reporting and review: pre-
market setting and submission review
International regulatory bodies have begun to address 
impediments to efficient and informative safety data 
capture. Many issues stem from incomplete reporting or 
uninformative over-reporting. An expanded toolbox of 
electronic submission, capture, and analysis of toxicities 
could improve these deficiencies. The existing manual 
reporting and submission systems and region-specific 
variations in regulatory requirements for reporting 
toxicities, coupled with an often-conservative inter pretation 
of the regulatory requirements by sponsors, has led initial 
efforts to focus on decreasing the number of safety reports 
submitted.168–170 The risk of missing genuine safety signals 
because of a large volume of irrelevant information is real, 
and extraneous data should not be submitted.
To improve efficiency of safety report submission, the 
TGA has implemented a shift from lengthy paper 
submissions to a single-page online submission. In 
Japan, safety reports of industry-sponsored registration 
trials are electronically submitted to the PMDA. The 
FDA recently did a pilot project to evaluate the feasibility 
of submitting safety reports (in the premarketing 
setting) as datasets that could be processed for analysis. 
The results of the pilot provide a technical framework 
for digitised submission of premarket safety reports 
based on existing standards used in the post-marketing 
setting via FDA’s Adverse event Reporting System 
(FAERS).171 The project is in its second phase of imple-
mentation, and the aim is to build a standard agency 
process for premarket safety submissions. Once the 
efficiency of submission and collection is addressed, the 
breadth of information to be captured needs to be 
outlined. In the EU, sponsors report serious, unexpected, 
and suspected adverse reactions to member states and to 
the centralised EVCTM. Non-commercial sponsors can 
use the EudraVigilance web-interface to electronically 
create and submit reports of serious, unexpected, and 
suspected adverse reactions, and the EudraVigilance 
system is used to manage and analyse information 
on suspected adverse reactions before and after 
authorisation.
Legislation has been advanced to support incorporation 
of the patient experience into drug development.172,173 
One area of great interest to the drug development 
community is the use of PROs to complement clinical 
assessment of adverse events. As discussed in section 2, 
PRO data can add to the overall benefit–risk assessment, 
particularly in the assessment of a drug that has similar 
efficacy to an available therapy but a more favourable 
toxicity profile.
The FDA and other international regulatory and health-
care policy leaders are collaborating with experts in the 
health outcomes research field to explore ways in which 
these data can assist regulatory review and inform product 
labeling.72,82,84,85 Incorporation of PRO data into labelling 
has begun at a very early stage.174 PROs are integral in 
TGA’s decision-making process, which uses the adopted 
EMA guidelines referenced above. In the USA, certain 
chronically administered drugs, such as those targeting 
the PD-1, PD-L1, and PD-L2 pathway include not only 
tabulated summaries of clinician-reported adverse events 
and their severity but the median time to onset of 
immune-mediated toxicities (nivolumab, pembrolizumab, 
atezolizumab, durvalumab, and avelumab package 
inserts). As collection and analysis tools become better 
refined, regulatory agencies agree that incorporation of 
these data into the review process is crucial to better 
describe safety and tolerability.
Patients or their advocates can also inform drug 
development during the trial design stage. The FDA has a 
variety of programmes that incorporate opportunities for 
patient and advocate involvement in the review process.175,176
Post-marketing pharmacovigilance: tools for moving 
forward
The post-marketing setting provides an opportunity to 
gain important additional information on safety and 
tolerability of cancer therapies. Although post-marketing 
data might benefit from flexibility and larger sources of 
data in a broader generalised population, these data are 
less controlled, adding uncertainty outside the rigour of 
clinical trials (figure 8). Safety data can be generated 
from off-label use of approved products by individual 
practitioners. Off-label prescribing of drugs and 
biologics is beyond the authority of the FDA and not 
regulated by TGA although the requirement to report 
adverse events remains. Once a drug has been approved, 
it is used in a wider population that might be older, 
sicker, and have different disease and patient 
characteristics than those enrolled in clinical trials.178 
The duration of therapy might also be longer than that 
of the patients on trial.
Data collected in the post-marketing phase can document 
long-term toxicities and tolerability, including low-grade 
toxicity over time, and is mandated by some regulatory 
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agencies. In Australia, the TGA mandates a 3-year period 
of post-marketing surveillance update reporting, which 
enhances assessment of cumulative toxicities of chronically 
administered products. The TGA is implementing a 
project using several IT solutions (eg, electronic 
submission of adverse event reports) to enhance their 
ability to identify and manage risk associated with post-
market activities.
FAERS in the USA is the main venue for submission 
of post-marketing safety information by health-care 
providers, patients, and other stakeholders. FAERS is 
subject to the same limitations of fatigue and bias seen 
in the pre-approval setting. In May 2008, the FDA also 
launched the Sentinel Initiative, which allows the 
agency to access information from large amounts of 
electronic health-care data (eg, electronic health records, 
insurance claims data, and registries) from a diverse 
group of data partners.179 These de-identified data can 
then be queried for analysis of safety signals.180
In Japan, the re-examination period prescribed by the 
Pharmaceuticals and Medical Devices Act is 10 years for 
orphan drugs, 8 years for new molecular entity drugs, 
and 4 years or 6 years for the other drug applications. 
The PMDA has constructed the MID-NET medical 
information database where electronic health record 
data, claims data from the national health insurance 
systems, and hospital inpatient expense data are stored. 
Since 2016, Japan has piloted use of this system for 
safety data, and they implemented full-scale use in 2018. 
Signals detected through any of these systems can be 
used to revise the package insert if assessed as necessary.
In the EU, the Good Pharmacovigilance Practices 
provide guidance on the reporting of suspected adverse 
reactions, even in special situations such as off-label 
use.181 These reports are submitted to EudraVigilance 
and are thus accessible for signal detection and 
evaluation. Additionally, mobile apps for patients and 
health-care professionals for reporting suspected 
adverse reactions are in development.182
Opportunities to leverage various types of real-world 
data to inform post-marketing safety exist in resources 
such as Sentinel, the American Society of Clinical 
Oncology’s CancerLinQ,183 Flatiron, Optum, OPeN, 
disease-specific patient registries, patient-generated 
data platforms (eg, Inspire, PatientsLikeMe, others), 
ORIEN, large big-data consortium projects in 
haematology like IMI2 HARMONY and other 
collaborative efforts (GNS Healthcare and the Multiple 
Myeloma Research Foundation, Biogen Idec, and 
Columbia University Medical Center), public and 
private claims databases, and institutional databases. 
Large big-data consortium projects that are integrating 
and analysing anonymous patient data from a high 
quality sources could provide important learnings on 
outcomes in haematological malignancies and support 
decision making of patients, policy makers, and 
clinicians. The fact that most records exist in 
unstructured text form presents a challenge to 
aggregation and interrogability of real-world data.
Recognising this challenge and that big-data analytics 
in other research fields can be borrowed for these 
purposes, the FDA launched the Information Exchange 
and Data Transformation initiative. The aim of this 
initiative is to expand and maintain an infrastructure 
for haematology–oncology data science and big-data 
analytics to support systems thinking in haematology–
oncology regulatory science research, and to devise and 
use solutions that will improve efficiency, reliability, and 
productivity.184 The initiative includes recruitment of 
experts in big-data analytics, provision of technical 
infrastructure itself, mentorship, and educational 
support, and stakeholder engagement. How the data 
obtained through this initiative will be analysed and 
interpreted requires much thought and consideration, 
but the potential to broaden data capture addresses 
many existing limitations to toxicity assessments. A 
collaboration between the FDA and CancerLinQ is 
underway to allow for the collection of real-world 
evidence when drugs are approved for a specific 
population; this evidence could inform labelling 
changes. The initial focus is on patients treated with 
checkpoint inhibitors, and other approaches in 
haematological malignancies are certainly relevant.
Figure 8: Weighing safety and efficacy in new drugs
Rigorous clinical trials allow for a measure of certainty about the data collected in a selected sample of the general 
population who will eventually use the therapy. The limited scope of these data at the time of marketing approval 
necessarily abbreviates the information upon which a regulatory decision must be made. Product regulation does not 
end at marketing approval, and technology is providing unprecedented opportunities to learn about safety and 
effectiveness from a greater variety of patients in the post-marketing setting using different data-capture platforms. 
These data are most often from uncontrolled settings and present a trade-off between large amounts of data in 
real-world populations on one hand, with challenges in data quality on the other. Adapted from Case Studies: Data 
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As familiarity is gained with how these systems work 
and how they need to be improved, they could, at 
minimum, enable increased data capture in the clinical 
trial setting. The FDA envisions the potential for novel 
data pipelines, including real-world data, to be 
submitted as part of a marketing application and taken 
into account during regulatory decision making.185,186 
The ability to harness these capabilities through 
pragmatic real-world trials would allow for a robust 
assessment of intervention outcomes in the broader 
population outside the traditional clinical trial 
context.187–189 The ultimate ability to collect real-world 
data in or out of the context of a clinical trial and to 
allow for labelling that better reflects the population to 
be served, while retaining the rigorous standards for 
protection of patient safety, is a topic debated in the 
regulatory community.190 At this point in time, such 
evidence might be the only pragmatic approach to 
answering questions about optimal dosing regimen, 
long-term use, and outcomes in subpopulations that 
often remain at the time of drug approval.191
The traditional method of adverse event reporting 
and analysis has served drug development well for 
decades but focuses on detection of extreme safety 
signals such as death and severe morbidity. An 
opportunity exists to use novel tools and technologies 
to build on past experience and improve regulatory 
assessment of adverse events in haematological 
malignancies, both before and after the marketing 
phase (panel 3). A more efficient process that is less 
time consuming and expensive than existing processes 
will include instruments and analytics that reflect 
tolerability (using PROs and other clinical outcomes), 
platforms to integrate all available data from trial 
participants and real-world patients alike, and analytics 
to interpret these data. Ultimately, these are funda-
mental to improving adverse event assessment in 
haematological malignancies and in solid tumours, 
with the goal of robust collection of relevant toxicity 
data that accurately informs drug development, 
approval, and treatment decisions for patients.
Section 6: Toxicity reporting in haematological 
malignancies in the real-world setting
Drug toxicity is established in clinical trials where 
standardised and detailed data about adverse events are 
collected prospectively and provide a solid foundation for 
the initial benefit–risk characterisation of new anticancer 
drugs. Improving toxicity assessment for haematological 
malignancies in clinical trials has been the primary focus 
of this Commission thus far. However, real-world 
evidence is relevant in toxicity assessment as well. In 
section 5, we explored some aspects of post-marketing 
surveillance of adverse events from a regulatory 
standpoint. In this section, we expand on the importance 
of toxicity data collected outside of clinical trials and 
identify opportunities to enhance this valuable resource 
in the real-world setting.
Collection and documentation of toxicity data in 
routine clinical practice
The detailed toxicity assessments that are required in 
clinical trials are impractical in routine clinical practice. 
Effective treatment of a haematological malignancy 
generally takes priority over adverse event assessments 
outside of clinical trials, particularly when a treatment is 
used within its approved indication. Adverse events are 
documented in health-care records if patients disclose 
their experience or if the treating health-care provider 
interprets symptoms and findings as consistent with an 
adverse drug reaction relevant enough to merit their 
documentation. Patients might minimise or omit some 
adverse events for fear of treatment modification or 
termination. Even when aware of serious adverse events, 
health-care professionals only report a small fraction of 
them to the health-care authorities responsible for 
pharmacovigilance.192 Real-world toxicity data is therefore 
likely to be more underreported than in clinical trials. 
Panel 3: Opportunities to advance regulatory assessment of adverse events in 
haematological malignancies, before and after marketing
Underreporting and incomplete capture of adverse events
Electronic submission of adverse event reports (all agencies)
This has been done by the TGA, done for commercial submissions only by PMDA, and is 
ongoing for the EMA and FDA.
Simplification of adverse event reporting
This has been done by TGA.
Incorporation of real-world evidence into pre-marketing and post-marketing safety (all agencies), 
using electronic health records, claims data, etc
The FDA uses the Sentinel database, the FDA adverse event reporting system, the 
Information Exchange and Data Transformation initiative (INFORMED), and partnerships 
with various platforms. The PMDA uses MID-NET.
Incorporation of patient voice, including PROs into pre-marketing and post-marketing safety 
(all agencies)
The 21st Century Cures Act requires the FDA to incorporate the patient perspective into 
drug and device development. Initiatives underway include draft guidances proposed for 
describing approaches to collection of patient or caregiver input on burden of disease or 
therapy, development of holistic sets of impact priorities for patients, and measures for 
analysis of these effects (2018–20); incorporation of patient input and data into risk-
benefit assessment (from clinical reviews; 2017); collaboration with the National Cancer 
Institute and drug development stakeholders to explore the PRO-CTCAE and involvmeent 
in workshops and other scientific working groups to advance PRO measurement tools, 
trial design and analytic methods (ongoing). The EMA and TGA use appendix 2 to the 
guideline on the evaluation of anticancer medicinal products in humans.172,173
Analysis of data obtained from anything other than a clinical trial
Ongoing efforts of the FDA include the INFORMED initiative, working groups to gather 
data on real-world evidence and PROs, and contribution to international collaboration to 
identify core outcome sets and PRO tools for use in the post-market setting.
FDA=US Food and Drug Administration. EMA=European Medicines Agency. PMDA=Japanese Pharmaceuticals and Medical 
Devices Agency. TGA=Australian Therapeutic Goods Administration. PROs=patient-reported outcomes.
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Agreement between the perception of a particular adverse 
event between patient and clinician is only moderate, 
again suggesting a bias in adverse event reporting by 
clinicians.193 These factors are serious limitations to the 
use of real-world data for toxicity assessment.
Role of databases and registries in collection of adverse 
event data
Much of what has been learned about toxicity in real-
world patients is drawn from several registries and 
databases that were originally designed to capture data for 
administrative purposes and outcomes research.194,195 A 
few examples of databases are the Surveillance, 
Epidemiology, and End Results (SEER) Program (which 
covers about 28% of the American population), the Mayo 
Clinic/University of Iowa MER/SPORE hospital-based 
patient cohort, the regional British Columbia Centre for 
Lymphoid Cancer database (covering lymphoma patients 
in the westernmost province of Canada), and national 
Danish and Swedish registries for several haematological 
malignancies.10,196–201 Some of the databases contain high-
quality of data in terms of accuracy and good database 
coverage.198,200 Although registration of detailed toxicity 
data is not the main purpose of these registries and 
databases, they are potentially valuable resources for 
studies of adverse events in real-world patient populations.
At a basic level, databases can be used to identify 
consecutive patients treated during a given time period, 
with subsequent back-tracking in medical records for 
adverse events. Databases can also be used to identify a 
relevant patient cohort for a prospective analysis, as done 
in a Norwegian study202 of patients treated with autologous 
stem-cell transplantation over a period of 20 years. 
Echocardiography of participating survivors revealed a 
higher than expected rate of left ventricular systolic 
dysfunction.202 These approaches add evidence for or 
against safety signals from other prospective or 
retrospective reports and provide the denominator of 
exposed patients needed to estimate the frequency of a 
particular adverse event. In Denmark and Sweden, 
unique identification numbers for each individual 
inhabitant, combined with nationwide patient registries 
that capture information on hospital contacts, enables 
nationwide toxicity studies. As an example, data from a 
Swedish study203 showed that patients surviving Hodgkin’s 
lymphoma after contemporary treatment had increased 
health-care use compared with the general population 
during the first decade after diagnosis, reiterating the 
burden of late toxicities in survivors of Hodgkin’s 
lymphoma. Again, these analyses are limited to adverse 
events that consistently require hospital contacts.
Relying on retrospective data collection mandates clear, 
consistent documentation of adverse events on the basis 
of consensus definitions in medical records and 
insensitivity to interpretational bias. Fatigue, insomnia, 
neuropathy, and pain are common symptoms in cancer 
patients that have profound negative effects on quality of 
life, but these subjective toxicities are not reliably assessed 
in retrospective studies.204 In such situations, absence of 
documentation cannot be taken as evidence of absence of 
the adverse event. As many patients with haematological 
malignancies become long-term survivors or take drugs 
continuously for months or years to control their disease, 
adverse events that are not life-threatening but 
nevertheless have a negative effect on quality of life 
become increasingly important. Indeed, quality matters 
as much as quantity of life to many patients with cancer, 
and data collected prospectively from real-world patients 
could better inform this difficult balance.205
The value of real-world toxicity data
Despite its limitations, there is substantial value to real-
world toxicity data and real-world side effects reported by 
patients and patient organisations (panel 4). Only a small 
proportion of patients with cancer (<3% of patients with 
breast, colorectal, lung, and prostate are enrolled in 
National Cancer Institute Clinical Trial Cooperative trials 
in the US) are treated within clinical trials because of 
restrictive inclusion criteria and limited availability of 
clinical trials.206 Patients volunteering for clinical trials are 
typically younger and have better performance status and 
fewer comorbidities than unselected real-world patients, 
even in settings where most patients are enrolled in a 
clinical trial.207–209 More importantly, clinical trials protocols 
often exclude a large proportion of potentially eligible 
patients on the basis of baseline organ function, 
comorbidities (including chronic infections), multiple 
concomitant medications with possible interactions, and 
certain prior therapies. These conditions limit extra-
polation of clinical trial results to real-world patients, 
particularly in situations of off-label use, and can lead to 
worse toxicity in clinical practice than initially anticipated 
from clinical trials.210 For example, patients with relapsed 
or refractory Hodgkin’s lymphoma who were previously 
treated with allogeneic stem-cell transplantation were 
Panel 4: Strengths and limitations of databases and 
registries for adverse event studies
Strengths
• Real-world patients
• Low study costs
• Time efficient studies with quick results
• Large number of patients for analyses
• Rare or late adverse events can be captured
• Results more likely to apply to all patients
Limitations
• Missing data and non-standardised data acquisition
• Biased
• Often sparse information on drug doses
• Not all toxicities are assessable
• Risk of uncontrollable confounding
• Patient reported outcomes rarely available
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excluded from the initial phase 1/2 trials of immune 
checkpoint inhibitors.211 Real-world data subsequently 
described a 30% incidence of acute graft-versus-host 
disease in patients treated with nivolumab for relapse 
after allogeneic stem-cell transplant, providing important 
practice-informing data.212
Follow-up in prospective trials often becomes reduced 
when the study meets its primary endpoint, limiting the 
detection of uncommon or late adverse events. The 
discovery of fatal progressive multifocal leukoenceph-
alopathy from JC polyoma virus reactivation in patients 
exposed to rituximab exemplifies the value of real-world 
data for post-marketing pharmacovigilance.16 The rapidly 
expanding number of drugs for haematological malig-
nancies, with some patient groups receiving several lines 
of treatment, underscores the necessity of collecting real-
world data that can be used to analyse drug interactions 
and cumulative toxicities. Many of these drugs will be used 
in sequence or combination, and real-world data could 
inform whether prior exposure to a particular treatment 
increases toxicity from the next line of therapy.
Databases can validate signals from other sources with 
excellent statistical power. For example, Chen and 
colleagues213 used the SEER database to estimate the 
incidence of heart failure or cardiomyopathy in 
45 537 elderly women receiving trastuzumab-containing 
chemotherapy for early breast cancer. In addition to 
confirming the results of randomised clinical trials in a 
general population (this study suggested the incidence of 
cardiac dysfunction might actually be greater in a 
population of elderly women), this particular toxicity 
endpoint was evaluated within a sample size that would 
never have been possible in the context of prospective 
clinical trials. The strengths and limitations of databases 
for the assessment of toxicity are summarised in panel 4.
Enhancing reporting of adverse events in databases: 
lessons from clinical trials
The most obvious way of integrating toxicity data into 
existing databases and registries is to treat adverse 
events similarly to other variables already being 
routinely collected and entered. However, there is more 
to the process than simply adding new fields for data 
entry. The main challenge with toxicity is the data itself: 
many toxicity endpoints are not necessarily objective or 
easy to measure, introducing subjectivity in the 
retrospective categorisation of toxicity. Adverse event 
reporting in clinical trials is typically based on the 
CTCAE. Ideally, real-world data should be collected 
with similar con sistency, but such consistency is not 
feasible in a routine clinical setting or in smaller 
community practices. However, the principles of 
collecting toxicity data systematically, objectively, and at 
multiple points over time can certainly be applied to 
real-world databases.
The main objective of database enhancement is to 
capture the clinically significant toxicities in a large 
population of patients. The process of data ascertainment 
should therefore not need to be as minutely detailed as in 
clinical trials. Also, increasing complexity will increase 
resource utilisation and cost. Capturing every possible 
adverse event for every patient would be impractical and 
resource-intensive, so some databases could choose to 
limit their focus to certain patient groups or toxicity 
categories. One example is to focus exclusively on 
potentially curable haematological malignancies where 
toxicity could derail the success of curative therapy. 
Another example is to collect a range of predetermined 
adverse events that are considered most relevant for a 
given group of patients, although the risk with this 
approach is missing important and unexpected toxicities. 
Finally, many administrative databases capture so-called 
sentinel events (ie, emergency room visit, hospital 
admission, discontinuation or change of prescription, 
death), which are more objective than many of the toxicity 
outcomes. This alternative could be more efficient than 
screening for the most serious toxicity, but ultimately 
requires going back to individual medical records.
CancerLinQ, a doctor-led ASCO initiative, is an 
example of a learning system for oncology that will offer 
new opportunities to explore real-world toxicities in 
large groups of patients.183 It was primarily developed to 
improve quality of care for patients treated in a routine 
clinical setting. Real-time analyses of real-world data 
were provided directly to the responsible doctor to 
facilitate more well informed decisions.214 By collecting 
data directly from electronic health-care records, 
CancerLinQ obviates the need for manual data 
abstraction, which makes it attractive to clinicians 
outside academia and ensures fast collection of large 
amounts of longitudinal data. However, the system 
relies on data documented in electronic records and 
therefore shares some of the limitations already 
discussed.215
Another lesson from clinical trials is that toxicity is best 
assessed prospectively and in real time, when the 
opportunities to query the clarity of the data, obtain 
additional information about a particular adverse event, 
or perform real-time checks for emerging toxicity signals 
still exist. Although this approach is feasible in databases 
such as CancerLinQ, other resources such as the large 
national databases and registries would not be able to 
accommodate these requirements without substantial 
investments.
Real-world patients’ perspectives on toxicity
Health-care professionals typically collect data to 
objectively measure the frequency and severity of adverse 
events, but each patient has a unique experience of 
adverse events in the context being diagnosed with 
cancer and expecting a clinical benefit from treatment. 
Although this experience is difficult to quantify, it must 
be accounted for better in future studies of real-world 
patients. As an example, grade 3 neuropathy might be an 
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acceptable trade-off for a patient with lymphoma 
receiving curative intent treatment but might not be 
acceptable to an elderly patient with myeloma who has 
postural instability and is receiving palliative treatment. 
Important elements that affect treatment decisions from 
a patient’s perspective are goal of treatment (curative vs 
palliative), magnitude of clinical benefit, potential 
toxicities, personality, and socioeconomic factors.205,216 In 
metastatic colorectal and lung cancer, patients’ 
expectations about effects of chemotherapy were studied 
in 1193 individuals,217 and most patients had not fully 
understood that chemo therapy was unlikely to cure their 
disease. Misconceptions of treatment goals alter the 
ability to make informed decisions about treatment and 
probably also affect the subjective experience and 
acceptance of associated toxicities. To fully understand 
the severity of toxicities, as experienced by the patients, 
and their effect on quality of life, toxicity data should be 
obtained from patients who are fully realistic about the 
magnitude of clinical benefit from a treatment. Patient 
organisations are also ideally positioned and increasingly 
engaged to collect and report real-world evidence on side-
effects that is based on data gathered from their 
constituency.25
Taking advantage of the patient experience to guide 
management of adverse events
Real-world adverse event data can also be enhanced by 
directly involving patients in the toxicity reporting 
process. The data generated by including patients in the 
actual reporting could provide a better perspective on the 
aspects of toxicity that patients, rather than health-care 
providers, find most relevant. The implementation of 
tools that measure PRO is possible today with the broad 
availability of mobile devices, and obtaining such data on 
a large scale would improve knowledge about real-world 
toxicity substantially. As technology improves and 
becomes more widespread and as the ageing population 
becomes more comfortable with technology, toxicity 
reporting could be enhanced. A consensus PRO system 
such as PRO-CTCAE that can translate and quantify 
information entered by the patient into clinically useful 
information has the potential to better describe real-
world patients’ symptoms and the effect of a particular 
symptom control intervention and to track progress over 
time.58,218 A process for optimising databases for future 
toxicity studies with integration of genomic data and 
PRO measures is outlined in figure 9.
Ultimately, clinical trials do not capture the entire 
picture of toxicities associated with a particular treatment. 
Real-world data are an important addendum to these 
data and constitute a resource that has not yet been 
exploited to its full potential. Many of the existing 
databases and registries can be harnessed to capture 
toxicity, but to maximise the clinical and research value 
of real-world toxicity data, consistency and standardisation 
procedures similar to those used in clinical trials should 
be applied. Initiatives like CancerLinQ that mine 
electronic health-care records for data provide new 
opportunities for big-data analyses of longitudinal data 
but cannot stand alone. Incorporation of PROs and 
integration of genomic and clinical data are initiatives 
that could clarify the effect of adverse events on the lives 
of patients. These initiatives will involve a significant 
Figure 9: Optimising databases for assessment of real-world toxicity
Optimising databases for future toxicity studies with integration of genomic data and clinical data (blue boxes), real-time toxicity data provided by health-care 
professionals (green boxes), and patient related outcome measures (red boxes).
Baseline clinical and
genomic data
















Chronic or late toxicities
observed by health-care
professional
Patient-reported toxicitiesAssessment of patient’s
treatment expectations
Acute toxicities observed 
by health-care professional
28 www.thelancet.com/oncology   Published online June 12, 2018   http://dx.doi.org/10.1016/S2352-3026(18)30051-6
The Lancet Haematology Commission
investment that will hopefully pay off with improved 
patient experiences and outcomes.
A call to action: targets and timelines for 
improving toxicity assessment in 
haematological malignancies
As a consequence of substantial changes in disease 
management approaches in the 21st century, tremendous 
progress with improved survival and cure rates in 
haematological malignancies has been achieved. 
However, new therapies, including chronically admin-
istered targeted agents and immunotherapies, among 
others, present new challenges. Patients are living with 
the challenge of managing not just their haematological 
malignancy, but also managing chronic therapy for their 
illness, with new types of acute, chronic, cumulative and 
late toxicities. This Commission convened a large, 
international group of expert authors representing 
patient advocates, clinicians, clinical researchers, reg-
ulators, statisticians and methodologists to address 
challenges in toxicity reporting in haematological 
malignancies. This initiative has evaluated current 
standards of toxicity reporting, the need to incorporate 
PROs, unique issues of toxicity in HSCT and in survivors 
of haematological malignancies, regulatory challenges 
and implementing real world toxicity analysis. We have 
identified a range of priority issues for improvement in 
these topic areas, and in this section we define our 
proposal for improvement and the path moving forward. 
Many of the proposed solutions are applicable across a 
broad variety of tumour types, but should be emphasised 
in haematological malignancies to keep pace with the 
changing nature of therapies for leukaemia, lymphoma, 
and myeloma. The challenges identified in this 
Commission and the specific immediate-term and long-
term solutions that constitute this Commission’s Call to 
Action are summarised in table 6.
Current standard and emerging therapies for haemato-
logical malignancies challenge traditional approaches to 
collecting and communicating drug-related adverse 
events. International efforts to harmonise systems for 
patient safety monitoring have been ongoing and need to 
continue to evolve. The standardisation of terminology 
using consensus definitions such as CTCAE34 remains 
essential, but defining adverse events in relation to timing 
of the drug exposure and the duration of these adverse 
events is now also imperative. Current methods of adverse 
event analysis focusing solely on maximum grade tables 
fall short in describing delayed, chronic, or cumulative 
effects that can limit long-term delivery of therapy. This 
issue is particularly relevant with the advent of immune 
therapies and their ensuing immune-related adverse 
events, which can be delayed, unpredictable, or prolonged. 
New approaches such as graphical displays from the NCI 
Web Reporting tool and longitudinal and AUC analyses 
such as those from ToxT36 have the potential to provide 
more comprehensive toxicity data in numerical and 
graphical form. International stakeholder consensus on 
the best metrics and representations is important, with the 
ultimate goal of standardising requirements for 
comprehensive and time-dependent toxicity data in 
publications and drug labels. Additionally, clinical trial 
design needs to accommodate delayed adverse events. 
Monitoring for dose-limiting toxicity should be expanded 
to two or three cycles before establishing a recommended 
phase-2 dosing schedule, or expansion cohorts should be 
encouraged to account for delayed adverse events in dose 
determination.
Changing therapies for haematological malignancies 
require new methods to assess, analyse, and interpret 
cancer drug safety and tolerability, which must incorporate 
the voice of the patient through use of PROs. Clinicians 
tend to underestimate the incidence and severity of 
symptoms compared with patients’ self-reports of similar 
information generated from PRO measures.78 Clinical 
trials with patients who have haematological malignancies 
do not typically include PRO assessments. Furthermore, 
historically, PRO tools did not have the flexibility to 
include items that captured the differing toxicity profiles 
seen with the treatments used in a specific haematological 
malignancy. Implementing tools to complement clinician-
recorded CTCAE grading in haematological malignancy 
trials (eg, PRO-CTCAE66), could enhance the assessment 
of tolerability. Further progress would come with improved 
integration and development of electronic collection of 
PROs through smartphones, wearable devices, and other 
technology that enable a patient to report adverse events 
in real time. Patient organisations would ideally be 
involved in the development and validation of these tools. 
Challenges exist not only in how PRO data should 
optimally be collected but in how it should be analysed. 
Lack of consensus as to the best analytical approaches for 
PRO data makes interpretation of the findings and cross-
trial comparisons challenging. Several international 
collaborative efforts are underway to identify core outcome 
sets, standard PRO analytic methods, and standard PRO 
protocol elements. International consensus on the 
approaches for use and analysis of PROs with clinician-
graded adverse events needs to be developed across 
clinical trials, with input from cooperative groups, patient 
organisations, regulatory bodies, and agencies.
HSCT presents expected toxicities, graft-versus-host 
disease, drug–drug inter actions, infectious adverse 
events, and longer-term adverse events affecting 
transplant survivors. The frequency of adverse events and 
their expectedness make reporting those that are of 
relevance an issue in transplantation. It is essential that 
post-HSCT adverse events be evaluated in the context of 
consensus definitions of their expectedness, depending 
on the graft source, transplant regimen, and other factors. 
Streamlined approaches are needed to capture and 
analyse these so that unexpected adverse events or 
increases in frequency of expected adverse events can be 
readily detected without causing undue burden of 
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reporting to clinicians and research staff. Automated 
approaches that harness data from electronic health 
records might be helpful in the future. In view of the 
number of interventions, adverse events from drug–drug 
interactions and infectious diseases are very complex in 
transplantation, and their severity is difficult to categorise. 
For infectious adverse events, scoring algorithms must 
include the number of infectious complications that now 
occur. Late-term effects of transplantation on survivors 
include sexual dysfun ction, infertility, and neurocognitive 
dysfunction, and the understanding of the incidence and 
character of these delayed effects is inadequate at present. 
A uniformed strategy to collect prospective data on 
fertility and pregnancy outcomes, and a standardised 
evaluation and grading of neuro cognitive function, as 
examples, would be important tasks for a consensus 
panel dedicated to improving the assessment of long-
term adverse events in HSCT.
Late-term and long-term toxicities affect many 
survivors of haematological malignancies. Intrinsic 
factors (age at diagnosis, sex, inherited genetic suscep-
tibilities) and life style factors (smoking, obesity, physical 
activity, and diet) both affect risks for late toxicity. 
Secondary malignancies, cardiovascular disease, and 
psychosocial impairments are major issues that have 
been reported primarily from national or institutional 
databases. Standardised, international, longitudinal 
patient cohorts of adult survivors of haematological 
malignancies are needed to collect real-life data that 
cannot come from limited follow-up of most clinical 
trials. Improved definition of non-relapse mortality is 
essential. Health-care delivery for survivors beyond 
surveillance for recurrence also remains a challenge. 
Evidence-based guidelines for optimal long-term follow-
up care of patients with haematological malignancies, 
ideally within the context of multidisciplinary clinics 
Concern Immediate-action solutions (1–5 years) Long-term solutions (more than 5 years)
Current processes in adverse 
event assessment (section 1)
Chronic, delayed, and cumulative 
adverse events are not well 
captured, leading to incomplete 
and potentially inaccurate 
toxicity assessment
• Design phase 1 trials with longer dose-limiting toxicity 
evaluation periods and increase use of adaptive designs that 
span phase 1/2
• Continue to develop, disseminate, validate, and apply 
longitudinal methods for analysis of adverse events
• Establish consensus on the best metrics and representations 
(tables, graphical representations, etc) of time-dependent 
adverse event data
• Standardise and require use of these metrics and displays in 
publications and drug labels
Patient-reported outcomes 
(PROs) in haematological 
malignancies (section 2)
PROs are not a standard part of 
toxicity assessment and 
therefore tolerability of therapies 
for haematological malignancies 
from the perspective of the 
patient is not assessed
• Include hypothesis-driven PROs in more haematological 
malignancy trials; increase use of PRO-CTCAE or other tools 
for capturing patient-reported symptomatic adverse events 
to better inform tolerability of novel and existing drugs for 
haematological malignancies, particularly those with chronic 
administration
• Explore and facilitate electronic capture of PROs in clinical 
trials through smartphones, wearable devices, and other 
technology
• Involve patient organisations in development and validation 
of disease-specific PRO tools
• Identify consensus analytic approaches to convey 
longitudinal PRO adverse event data
• Complement clinician-graded CTCAE reports with 
patient-reported symptomatic adverse event data to 
improve understanding of tolerability
• Standardise these approaches to the analysis of PROs across 
cancer trials internationally
Toxicities in HSCT (section 3) Cumbersome reporting of the 
myriad of expected adverse 
events in the HSCT setting is a 
barrier to performing clinical trials
• Develop consensus on expected adverse events after HSCT 
based on registry data
• Prioritise targeted approaches that focus on unique, 
potentially relevant adverse events, including unexpected 
drug interactions and neurocognitive effects
• Develop automated approaches that can recognise data 
routinely captured in the electronic health record as 
expected toxicity data after HSCT or highlight provider 
attention to unexpected, unique, and potentially relevant 
adverse events
Long-term toxicity and 
survivorship in haematological 
malignancies (section 4)
The description and management 
of cumulative and late toxicities in 
survivors of haematological 
malignancy is inconsistent, 
inadequate, or absent
• Develop and support infrastructure to collect data for adult 
survivors of haematological malignancies, such as 
longitudinal patient cohorts
• Standardise the use and content of survivorship care plans
• Link PRO, delayed, or long-term complications of 
haematological malignancies, and their baseline treatment 
in electronic medical records
• Increase availability of multidisciplinary survivorship clinics
• Sustain funding of survivorship research
Haematological malignancies 
and regulatory approval 
(section 5)
Meaningful adverse events of 
therapy for haematological 
malignancies are often 
underreported to regulatory 
agencies, while reporting of 
uninformative adverse events 
might obscure true safety signals
• Simplify and make electronic the submission of all adverse 
event reports
• Develop better systems for collection and analysis of data 
obtained from the trial, post-marketing or non-trial setting
• Attain international regulatory consensus on reduction of 
uninformative adverse event reports to prioritise relevant 
toxicity data
• Incorporate patient experience from trial and non-trial data, 
including real-world evidence, to inform both the 
pre-marketing and post-marketing safety evaluation
Toxicity reporting in 
haematological malignancies 
and the real-world setting 
(section 6)
Toxicities affecting patients with 
haematological malignancies in 
routine clinical practice are 
difficult to capture and analyse 
on a large scale
• Optimise the systematic, objective collection of toxicity data 
at multiple points over time in real world databases
• Explore real-world toxicities in large groups of patients using 
learning systems and real-time analyses from tools such as 
CancerLinQ
• Collaborate with informaticists to develop electronic health 
record systems that reliably capture relevant adverse event 
(both doctor-reported and PRO) in patients receiving 
therapy for haematological malignancies off study in a 
standardised, manageable format
• Use systems above to guide adverse event management and 
symptom control in patients with haematological 
malignancies
CTCAE=Common Terminology Criteria for Adverse Events. HSCT=haemopoietic stem-cell transplant.
Table 6: Goals of this Commission: summary of targets and timelines for improvements in adverse event assessment in haematological malignancies
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dedicated to survivorship and with the involvement of 
patient support groups, are needed.
Making toxicity assessment in haematological 
malignancies more comprehensive and accurate without 
adding logistical complexity and burden is a challenge 
relevant to regulatory bodies in all parts of the world.169,170 
Although each country and agency has its own nuanced 
regulatory process, there are many similarities across 
bodies such as the FDA, EMA, PMDA, and TGA. Efforts 
have been made to improve the utility of safety reports 
and increase the efficiency of reporting process, but there 
are multiple issues. Unnecessary safety reports, often the 
result of conservative interpretation of regulatory 
requirements, are noise that mask true safety signals in 
the reporting system. The risk of missing genuine safety 
signals due to a large volume of irrelevant information 
exists. The time and financial resources required for 
adverse event reporting are burdensome to patients, 
investigators, nurses, and clinical research professionals 
internationally. Meanwhile, relevant information on drug 
tolerability, such as drug interruptions, discontinuations, 
or dose reductions are not always reported. Regulatory 
agencies have also recognised the need to incorporate 
PRO into tolerability determination, and are involving 
patient organisations in implementation. The impedi-
ments to efficient and informative safety data capture 
must be discussed at an international level, and an 
expanded toolbox with simplified, uniform electronic 
submission is needed. Most regulatory agencies support 
data collection in the post-marketing setting as an 
opportunity to gain important additional information on 
safety and tolerability and revise the package insert of a 
drug if necessary, but these are subject to reporter fatigue 
and bias, and their existence is also often unknown to 
patients. Future directions include pursuing opportun-
ities to leverage a variety of real-world database tools and 
big-data resources as novel pipelines of data to improve 
post-marketing toxicity assessment.
Only a small subset of patients with cancer are treated 
in clinical trials. Additionally, trial populations are often 
younger or healthier than those with disease in the 
general population, and follow-up is limited to detect 
uncommon or late toxicity. The use of real-world data 
from patients, patient advocacy organisations, and 
databases is therefore important to improve toxicity 
assessment. Incomplete registrations, inconsistent 
terminology and document ation, incomplete follow-up, 
biased data, and caveats of retrospective causality 
assessment are all substantial limitations of real-world 
data. Despite these challenges, harnessing registries and 
databases to improve toxicity evaluation portends benefit. 
Optimising the systematic and objective collection of 
adverse event data over multiple timepoints in real-world 
databases would facilitate the capture of clinically 
significant toxicities in large populations of patients. This 
could be practicably carried out by focusing on a range of 
predetermined adverse events, certain patient groups, or 
toxicity categories. Learning systems such as the 
CancerLinQ183 offer the opportunity to study toxicity in 
large groups of patients by culling data from electronic 
health records. Real-world adverse event data is enhanced 
with the direct involvement of patients and patient 
organisations in the toxicity reporting process. Ultimately, 
one goal would be to develop electronic systems that can 
capture both clincal provider-reported (clinical providers 
include doctors, nurse practitioners, physician assistants, 
etc) and PRO toxicity data in a standardised format for 
patients being treated off study. Consistency in 
standardisation procedures similar to, but perhaps not as 
rigorous, as those used in clinical trials should be applied 
and further developed. This unique data would be 
valuable for the characterisation of toxicity in non-study 
patients with haematological malignancies, and it could 
potentially be harnessed to guide adverse event 
management and symptom control in the clinic.
The success in outcomes and survival in many 
haematological malignancies is historically unparalleled 
and fuelled by scientific discovery and implementation. 
Measures to address the broad facets of toxicity 
assessment, as outlined in table 6, must be prioritised 
and further developed to ultimately enhance accurate, 
comprehensive, patient-centred toxicity rep orting that 
will meaningfully inform the care of patients with 
haematological malignancies.
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